書籍詳細

Part1 Guidance 臨床からみたプロトンポンプ阻害薬の意義

P.24 掲載の参考文献

• 1) 三好秋馬, 谷内昭, 後藤由夫ほか:Omeprazole の十二指腸潰瘍に対する臨床的有用性の検討-多施設二重盲検法による Famotidine との比較-. 薬理と治療 16 (suppl 3):563-582, 1988.

• 2) 竹本忠良, 並木正義, 松尾裕ほか:十二指腸潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討-多施設二重盲検法によるFamotidineとの比較-. 臨床成人病 21:613-631, 1991.

• 3) 中澤三郎, 並木正義, 松尾裕ほか:十二指腸潰瘍に対するE3810の臨床的有用性の検討-多施設二重盲検によるFamotidineとの比較-. Clin Eval 21:361-382, 1993.

• 4) Graham DY, colon-Pagan J, Morse RS et al:Ulcer recurrence following duodenal ulcer healing with omeprazole ranitidine, or placebo:a double blind, multicenter, 6-months study. Gastroenterol 102:1289-1294, 1992.
  pubmed

• 5) Farup PG, Rosseland AR, Halvorsen L et al:Duodenal ulcer treated with omeprazole:healing and relapse rate. Scand J Gastroenterol 24:1107-1112, 1989.
  pubmed

• 6) Lauritsen K, Andersen BN, Laursen LS et al:Omeprazole 20mg three days a week and 10mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. Gastroenterology 100:663-669, 1991.

• 7) Goh KL, Boonyapisit S, Lai KH et al:Prevention of duodenal ulcer relapse with omeprazole 20mg daily:A randomized double-blind, placebo-controlled study. J Gastroenterol Hepatol 10:92-97, 1995.

• 8) Bianchi Porro G, Corinaldesi R, Lazzaroni M et al:Long term treatment with omeprazole 20mg three days a week or 10mg daily in the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 8:541-548, 1994.

• 9) Di Mario FD, Battaglia G, Leandro G et al:Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials. Dig Dis Sci 41:1108-1131, 1996.

• 10) Eriksson S, Langstrom G, Rikner L et al:Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux esophagitis:a meta-analysis. Eur J Gastroenterol Hepatol 7:467-475, 1995.
  pubmed

• 11) 三好秋馬, 谷内昭, 後藤由夫ほか:Omeprazoleの胃潰瘍に対する臨床的有用性の検討-多施設二重盲検法によるFamotidineとの比較-. 薬理と治療 16 (suppl 3):S543-S561, 1988.

• 12) 竹本忠良, 並木正義, 後藤由夫ほか:胃潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討-多施設二重盲検による Famotidine との比較-. 臨床成人病 21:327-345, 1991.

• 13) 中澤三郎, 並木正義, 松尾裕ほか:胃潰瘍に対するE3810の臨床的有用性の検討-多施設二重盲検によるFamotidineとの比較-. Clin Eval 21:337-359, 1993.

• 14) 浅木茂, 佐藤彰, 櫻田弘之ほか:プロトンポンプ阻害剤 (タケプロン(R)) の胃潰瘍に対する有用性の検討-初期治療におけるS2移行率, 維持療法, 継続治療における再発率-. 薬理と治療 25:1449-1456, 1997.
  Medical*Online

• 15) 小島紘一, 松田昌幸, 石井恭生ほか:プロトン. ポンプ阻害剤ランソプラゾールの消化性潰瘍に対するS2移行率と再発率の検討. 医学と薬学 35:1077-1085, 1996.

• 16) 三澤正, 千々岩芳春, 原田直孝ほか:オメプラール投与による胃潰瘍, 十二指腸の療痕像および再発に関する検討. 新薬と臨床 46:418-426, 1997.

• 17) Tanaka M, Maruoka A, Chijiwa Y et al:Endoscopic ultrasonographic evaluation of gastric ulcer healing on treatment with protonpump inhibitors versus H2-receptor antagonists. Scand J Gastroenterol 129:1140-1144, 1994.

• 18) Walan A, Bader JP, Classen M et al:Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320:69-75, 1989.
  pubmed

• 19) 関口利和, 西岡利夫, 草野元康ほか:逆流性食道炎に対するOmeprazoleの臨床評価. 薬理と治療 16 (suppl 3):745-755, 1988.

• 20) 岸清一郎, 辻康弘, 伊藤進ほか:逆流性食道炎に対するOmeprazoleの臨床的有用性の検討. 薬理と治療 16 (suppl 3):757-765, 1988.

• 21) 関口利和, 松崎勉, 堀越勤ほか:逆流性食道炎に対するLansoprazoleの臨床評価. Ther Res 12:191-213, 1991.
  Medical*Online

• 22) 岸清一郎, 伊藤進, 梶本宜史ほか:逆流性食道炎に対するLansoprazoleの臨床的有用性の検討. Prog Med 10:3197-3206, 1990.

• 23) 遠藤光文, 関口利和, 中村孝司ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749 の臨床的有用性の検討-第一報治療効果の検討-. 臨床成人病 29:805-817, 1999.

• 24) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するOmeprazoleの臨床評価 (第2報) -再発予防効果と安全性の検討-. 臨床医薬 6:1387-1404, 2000.

• 25) 遠藤光文, 関口利和, 中村孝司ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749の臨床有用性の検討. 臨床成人病 29:959-977, 1999.

• 26) Laursen LS, Havelund T, Bondesen S et al:Omeprazole in the long-term treatment of gastro-esophageal reflux disease. A double blind randomized dose-finding early study. Scand J Gastroenterol 30:839-846, 1995.

• 27) Dent J, Yeomans ND, Mackinnon M et al:Omeprazole v ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut 35:590-598, 1994.

• 28) Sontag SJ, Kogut DG, Fleischmann R et al:Lansoprazole prevents recurrent of erosive reflux esophagitis previously resistant to H2-RA therapy. Am J Gastroenterol 91:1758-1765, 1996.
  pubmed

• 29) Vigneri S, Termini R, Leandro G et al:A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333:1106-1110, 1995.

• 30) Carlsson R, Galmiche JP, Dent J et al:Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drug a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 11:473-482, 1997.

• 31) 三好秋馬, 青木照明, 中島光好ほか:上部消化管出血に対するOmeprazol注射剤の臨床的研究-Famotidine注射剤を対照とした二重盲検比較試験-. 薬理と治療 23(suppl):1593-1608, 1995.

• 32) Mohamed SA, al Karawi MA:Omeprazole versus histamine H2 receptor antagonists in the treatment of acute upper non-variceal bleeding. Hepatogastroenterology 43:863-865, 1996.
  pubmed

• 33) Daneshmend TK, Hawkey CJ, Langman MJ et al:Omeprazole versus placebo for acute upper gastrointestinal bleeding randomised double blind controlled trial. BMJ 304:143-147, 1992.
  pubmed

• 34) Lasky MR, Metzler MH, Phillips Jo:A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 44:527-533, 1998.
  pubmed

• 35) Hopkins RJ, Girardi LS, Turney EA et al:Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence. A review. Gastroenterology 110:1244-1252, 1996.
  pubmed

• 36) Laine L, Hopkins RJ, Girardi Ls:Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overtstated?A meta-analysis of vigorously designed trials. Am J Gastroenterol 93:1409-1415, 1998.

• 37) Lind T, Megraud F, Unge P et al:The MACH2 study:Role of omeprazol in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253, 1999.
  pubmed

P.29 掲載の参考文献

• 1) 谷禮夫:胃酸分泌抑制剤効力比較の解析. 24時間胃内pHモニタリング試験の成績を中心に. Pharma Medica 19:189-199, 2001.

• 2) Hirschowitz BI, Keeling D, Lewin M et al:Pharmacological aspects of acid secretion. Dig Dis Sci 40 (2 suppl):3S-23S, 1995.

• 3) Jones R, Bytzer P:Review article:acid suppression in the management of gastro-oesophageal reflux disease. an appraisal of treatment options in primary care. Aliment Pharmacol Ther 15:765-772, 2001.
  pubmed

• 4) Mardh S, Song YH, Wallmark B:Effects of some antisecretory drugs on acid production, intracellular free Ca2+, and cyclic AMP production in isolated pig parietal cells. Scand J Gastroenterol 23:977-982, 1988.
  pubmed

• 5) Larsson H, carlsson E, Junggren U et al:Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology 85:900-907, 1983.
  pubmed

• 6) Coruzzi G, Bertaccini G:Antisecretory activity of omeprazole in the conscious gastric fistula cat:comparison with famotidine. Pharmacol Res 21:499-506, 1989.
  pubmed

• 7) Elander B, Fellenius E, Leth R et al:Inhibitory action of omeprazole on acid formation in gastric glands and on H+, K+-ATPase isolated from human gastric mucosa. Scand J Gastroenterol 21:268-272, 1986.

• 8) 大原秀一, 本郷道夫, 浅井茂ほか:24時間胃内 pHモニターによるファモチジンおよびオメプラゾールの胃内pHに対する影響. 日本消化器病学会雑誌 85:1353-1359, 1988.

• 9) 渡辺伸一郎, 平沢豊, 竹田昌弘ほか:Famotidine 40mg 1日1回就寝前投与の24時間胃内酸度に及ぼす影響. 健常人における検討. 消化器科 8:234-242, 1988.

• 10) 吉田智治, 沖田極, 原田稔也ほか:逆流性食道炎に対するオメプラール錠の有用性の検討, 封筒法を用いた無作為割り付けによるH2ブロッカーとの比較. 新薬と臨床 48:1431-1440, 1999.

• 11) 羽生泰樹, 清田啓介, 浅田全範ほか:軽症逆流性食道炎治療におけるオメプラゾールとファモチジンの無作為比較対照試験. 新薬と臨床 49:1072-1078, 2000.
  Medical*Online

• 12) van Pinxteren B, Numans ME, Bonis PA et al:Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review) Cocbrane Database Syst Rev 4:CD002095, 2001.
  pubmed

• 13) 吉田行雄, 木平健, 木村健:プロトンポンプ・インヒビター (PPI) の酸分泌抑制作用24時間pHモニタリングによる検討. 胃潰瘍・十二指腸潰瘍. GI Research 1:239-245, 1993.

• 14) Williams MP, Pounder RE:Review article:the pharmacology of rabeprazole. Aliment Pharmacol Ther 13 (suppl 3):3-10, 1999.

• 15) Netzer P, Gaia C, Huluk TH et al:Effect of repeated bolus injection vs continuous infusion of high dose omeprazole and ranitidine on intragastric pH for 72 hours. Gastroenterology 112 (suppl):A 233, 1997.

• 16) Li Y, Sha W, Nie Y et al:Mechanism and control of gastric mucosal injury and bleeding. Effect of intragastric pH on control of peptic ulcer bleeding. J Gastroenterol Hepatol 15:148-154, 2000.

• 17) Labenz J, Peitz U, Leusing C et al:Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding:a prospective randomized controlled study. Gut 40:36-41, 1997.
  pubmed

• 18) 浜向伸治, 谷禮夫, 三輪剛:Lansoprazoleの胃酸分泌に対する臨床薬理学的検討24時間胃内pHモニタリングによる朝投与と夜投与の比較. 薬理と治療 19:925-931, 1991.

• 19) Peghini PL, Katz PO, Bracy NA et al:Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767, 1998.
  pubmed

• 20) Xue S, Katz PO, Banerjee P et al:Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 15:1351-1356, 2001.
  pubmed

• 21) Katsube T, Adachi K, Kawamura A et al:Helicobacter pylori:infection influences nocturnal gastric acid breakthrough. Aliment Phormacol Ther 14:1049-1056, 2000.
  pubmed

P.34 掲載の参考文献

• 1) Lazarou J, Pomeranz BH, corey PN:Incidence of adverse drug reactions in hospitalized patients:a meta-analysis of prospective studies. JAMA 279:1200-1205, 1998.
  pubmed

• 2) 中村祐輔:ゲノム情報に基づく21世紀のオーダーメイド医療. 実験医学 18:1650-1654, 2000.
  Medical*Online

• 3) 千葉寛:薬物代謝に関しての薬物間相互作用の基礎知識. 治療 76:2214-2220, 1994.
  Medical*Online

• 4) Ishizaki T, Horai Y:Review article:cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13 (suppl 3):27-36, 1999.

• 5) Kupfer A, Preisig R:Pharmacogenetics of mephenytoin:a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759, 1984.
  pubmed

• 6) Wedlund PJ, Aslanian WS, McAllister CB et al:Mephenyto in hydroxylation deficiency in Caucasians:frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773-780, 1984.
  pubmed

• 7) Sanz EJ, Villen T, Alm C et al:S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45:495-499, 1989.

• 8) Jacqz E, Dulac H, Mathieu H:Phenotyping polymorphic drug metabolism in the French Caucasian population, Eur J Clin Pharmacol 35:167-171, 1988.
  pubmed

• 9) Horai Y, Nakano M, Ishizaki T et al:Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects:Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207, 1989.
  pubmed

• 10) Yasuda S, Horai Y, Tomono Y et al:Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole inrelation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 58:143-154, 1995.

• 11) Sohn DR, Kwon JT, Kim HK et al:Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Clin Pharmacol Ther 61:574-582, 1997.

• 12) Sakai T, Aoyama N, Kita T et al:CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721-727, 2001.
  pubmed

• 13) Aoyama N, Tanigawara Y, Kita T et al:Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 34 (suppl XI):80-83,1999.

P.39 掲載の参考文献

• 1) 山田明, 乳原善文, 香取秀幸ほか:高度腎不全患者におけるランソプラゾールの効果と血中動態. Ther Res 17:1423-1427, 1996.
  Medical*Online

• 2) 竹山泰守, 松井敏幸, 八尾恒良ほか:胃体部潰瘍に対するH2-受容体拮抗剤とプロトンポンプインヒビターの効果比較;prospective controlled study. 日消誌 96:502-510, 1999.
  Medical*Online

• 3) 安武晃一, 西崎朗, 姜京富ほか:酸分泌抑制剤(ヒスタミンH2受容体拮抗剤, プロトンポンプインヒビター) による上部消化管の潰瘍性病変患者の自覚症状「疼痛」消失期間に関する検討. 新薬と臨床 48:1266-1274, 1999.

• 4) 羽生泰樹:逆流性食道炎における医療判断学による費用効果分析. 実験治療 661:49-52, 2001.

• 5) 末兼浩史, 飯田三雄, 中村昌太郎ほか:胃MALTリンパ腫に対するHelicobacter Pylori除菌治療後の経過;内視鏡・EUS像からみた治療効果の予測. 胃と腸 34:1397-1409, 1999.

P.43 掲載の参考文献

• 1) Nelson EC, Moh JJ, Batalden PB et al:Improving health care, Part I:The clinical value compass. Jt Comm Qual Improv 22:243-258, 1996.

• 2) 池田俊也:費用-効果分析の結果をいかに解釈するか. 薬剤経済学研究の政策決定への利用可能性と課題. 薬剤疫学 6:59-68, 2001.

• 3) Harris RA, Kuppermann M, Richter JE et al:Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis:a cost-effectiveness analysis. Am J Gastroenterol 92:2179-2187, 1997.

• 4) 羽生泰樹:日本におけるGERD薬剤治療の費用効果分析. プロトンポンプ阻害剤 (PPI) とH2受容体拮抗剤 (H?RA) の比較評価. Ther Res 21:1400-1404, 2000.

• 5) Dean BB, Siddique RM, Yamashita BD et al:Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm 58:1338-1346, 2001.
  pubmed

• 6) Condra LJ, Morreale AP, stolley SN et al:Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Manag Care 5:631-638, 1999.
  pubmed

Part2 Profile 薬理作用からみたプロトンポンプ阻害薬と臨床への有用性

P.50 掲載の参考文献

• 1) Pedersen PL, Carafoli E:Ion motive ATPases. I. Ubiquity, properties, and significance to cell function. TIBS 12:146-150, 1987.

• 2) 漆谷徹郎, 長尾拓:壁細胞におけるシグナル伝達とプロトンポンプの細胞内輸送. 日本薬理学会雑誌 110:303-313, 1997.

• 3) Sachs G:The gastric H/K ATPhase. In:Physiology of the Gastrointestinal Tract, ed by Johnson LR, Raven Press, New York, 1994, pp1119-1138.

• 4) Sachs G, shin JM, Briving c et al:The pharmacology of the gastric acid pump:The H+/K+ ATPase. Annu Rev Pharmacol Toxicol 35:277-305, 1995.

• 5) 浅野真司:胃プロトンポンプの機能と構造. 薬学雑誌 117:379-393, 1997.

• 6) Hoogerwerf WA, Pasricha PJ:Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal reflux disease. In:The Pharmacological Basis of Therapeutics, ed by Hardman JG, Limbird LE, McGraw-Hill, New York, 2001, pp1005-1020.

• 7) Muraoka A, Kaise M, Guo YJ et al:Canine H+/K+-ATPase α subunit gene promoter:Studies with canine parietal cells in primary culture. Am J Physiol 271:G1104-G1113, 1996.

• 8) 前田正知:胃粘膜プロトンポンプ遺伝子と転写調節. 薬学雑誌 116:91-105, 1996.

P.59 掲載の参考文献

• 1) Wolfe MM, Sachs G:Acid suppression:optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 118 (2 suppl 1):S9-S31, 2000.

• 2) Besancon M, Simon A, Sachs G et al:Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272:22438-22446, 1997.
  pubmed

• 3) Stedman CA, Barclay ML:Review article:comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963-978, 2000.
  pubmed

• 4) Andersson T, Andren K, Cederberg C et al:Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 29:557-563, 1990.
  pubmed

• 5) Landes BD, Petite JP, Flouvat B:clinical pharmacokmetics of lansoprazole. Clin Pharmacokinet 28:458-470, 1995.

• 6) Brummer RJ, Geerling BJ, Stockbrugger Rw:Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 42:2132-2137, 1997.
  pubmed

• 7) Andersson T:Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28, 1996.
  pubmed

• 8) Delhotal-Landes B, Flouvat B, Duchier J:Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45:367-371, 1993.
  pubmed

• 9) Tucker GT:The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 8(suppl 1):33-38, 1994.

• 10) Unge P, Andersson T:Drug interactions with proton pump inhibitors. Drug Saf 16:171-179, 1997.
  pubmed

• 11) Ishizaki T, Horai Y:Review article:cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13(suppl 3):27-36, 1999.

• 12) Furuta T, Shirai N, Takashima M et al:Effects of genotypic differences in CYP2C19 status on curerates for Helicobacter Pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11:341-348, 2001.

• 13) Kokufu T, Ihara N, Sugioka N et al:Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 48:391-395, 1995.
  pubmed

• 14) Andersson T, Bergstrand R, Cederberg C et al:Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 101:943-947, 1991.
  pubmed

• 15) Huang JQ, Hunt RH:pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med 69:159-174, 1996.
  pubmed

• 16) Tolman KG, Sanders SW, Buchi KN et al:The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 24:65-70, 1997.
  pubmed

• 17) Bruley des Varannes S, Levy P, Lartigue S et al:Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. aliment Pharmacol Ther 8:309-314, 1994.
  pubmed

• 18) Blum RA, Shi H, Karol MD et al:The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 19:1013-1023, 1997.

• 19) Verdu EF, Fraser R, Armstrong D et al:Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 29:1065-1069, 1994.
  pubmed

• 20) Geus WP, Mulder PG, Nicolai JJ et al:Acid inhibitory effects of omeprazole and lansoprazole in Helicobacter. pylori-negative healthy subjects. aliment Pharmacol Ther 12:329-335, 1998.
  pubmed

• 21) Williams MP, sercombe J, Hamilton MI et al:A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male sublects. Aliment Pharmacol Ther 12:1079-1089, 1998.

• 22) Vcev A, Stimac D, Vceva A et al:Lansoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med Croatica 51:171-174, 1997.
  pubmed

• 23) Castell Do, Richter JE, Robinson M et al:Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 91:1749-1757, 1996.

• 24) Hatlebakk JG, Berstad A, carling L et al:Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 28:224-228, 1998.

• 25) Mee As, Rowley JL:Rapid symptom relief in reflux oesophagitis:a comparison of lansoprazole and omeprazole. Aliment Pharmaocol Ther 10:757-763, 1996.
  pubmed

• 26) Mulder CJ, Dekker W, Gerretsen M:Lansoprazole 30mg versus omeprazole 40 mg in the treatment of renux oesophagitis grade II, III and IVa (a Dutch multicentre trial) . Dutch Study Group. Eur J Gastroenterol Hepatol 8:1101-1106, 1996.

• 27) Dekkers CP, Beker JA, Thjodleifsson B et al:Comparison of rabeprazole 20mg versus omeprazole 20mg in the treatment of active duodenal ulcer:a European multicentre study. Aliment Pharmacol Ther 13:179-186, 1999.

• 28) Carling L, Axelsson CK, Forssell H et al:Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis:along-term comparative study. Aliment Pharmacol Ther 12:985-990, 1998.

• 29) Dekkers CP, Beker JA, Thjodleifsson B et al:Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther 12:789-795, 1998.

• 30) Chang FY, Chiang CY, Tam TN et al:Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. J Gastroenterol Hepatol 10:595-601, 1995.
  pubmed

• 31) Dobrilla G, Piazzi L, Fiocca R:Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse:a randomized, multicenter, double-masked trial. Clin Ther 21:1321-1332, 1999.
  pubmed

• 32) Ekstrom P, Carling L, Unge P et al:Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study. Scand J Gastroenterol 30:210-215, 1995.
  pubmed

• 33) Pipkin GA, Williamson R, wood JR:Review article:one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther 12:823-837, 1998.
  pubmed

• 34) Miwa H, Ohkura R, Murai T et al:Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicohacter pylo ri infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 13:741-746, 1999.

• 35) Jones R, crouch SL:Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 13:413-419, 1999.
  pubmed

• 36) Prakash A, Faulds D:Rabeprazole. Drugs 55:261-267;discussion 268, 1998.

• 37) Spencer CM, Faulds D:Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 48:404-430, 1994.
  pubmed

• 38) Langtry HD, Wilde MI:Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 54:473-500, 1997.
  pubmed

• 39) Wilde MI, McTavish D:Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 48:91-132, 1994.
  pubmed

• 40) Koury SI, Stone CK, La Charite DD:Omeprazole and the development of acute hepatitis. Eur J Emerg Med 5:467-469, 1998.
  pubmed

• 41) Odou P, Martin P, Membre S et al:Omeprazole-induced leukopenia. A case report. J Clin Pharm Ther 24:317-321, 1999.
  pubmed

• 42) Yip D, Kovac S, Jardine M et al:Omeprazole-induced interstitial nephritis. J Clin Gastroenterol 25:450-452, 1997.
  pubmed

• 43) Schonhofer PS, Werner B, Troger U:Ocular damage associated with proton pump inhibitors. BMJ1314:1805, 1997.
  pubmed

• 44) Garcia Rodriguez LA, Mannino S, Walland er MA et al:A cohort study of the ocular safety of anti-ulcer drugs. Br J Clin Pharmacol 42:213-216, 1996.

P.64 掲載の参考文献

• 1) Suzuki M, Mori M, Miura S et al:Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Raaic Biol Med 21:727-731, 1996.
  pubmed

• 2) Suzuki M, Nakamura M, Mori M et al:Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicohacter pylor. J Clin Gastroenterol 20 (suppl 2):S93-S96, 1995.

• 3) Suzuki M, Mori M, Fukumura D et al:Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extract of Helicobacter pylori. J Gastroenterol Hepatol 14:27-31, 1999.
  pubmed

• 4) Wandall JH:Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation and translocation of cytochrome b-245. Gut 33:617-621, 1992.
  pubmed

• 5) Yoshida N, Yoshikawa T, Tanaka Y et al:A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14(suppl 1):74-81, 2000.

• 6) Ohara T, Arakawa T:Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci 44:1710-1715, 1999.
  pubmed

• 7) Scaringi L, Cornacchione P, Fettucciari K et al:Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol 44:204-214, 1996.
  pubmed

• 8) Logan RPH, Walker MM, Misiewicz JJ et al:Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36:12-16, 1995.

• 9) Uemura N, Okamoto S, Yamamoto S et al:Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 14:1345-1352, 2000.
  pubmed

• 10) Suzuki M, Suzuki H, Kitahora T et al:Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis. Aliment Pharmacol Ther 16:159-165, 2002.
  pubmed

• 11) Heinzow U, Schlegelberger T:Omeprazole in ulcerative colitis. Lancet 343:477, 1994.
  pubmed

P.69 掲載の参考文献

• 1) Larsson H, Carlsson E, Mattsson H et al:Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90:391-399, 1986.

• 2) Prinz C, Scott DR, Hurwitz D et al:Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am Physiol 267:G663-G675, 1994.
  pubmed

• 3) Ichikawa T, Ishihara K, Saigenji K et al:Stimulation of mucus glycoprotein biosynthesis in rat gastric mucosa by gastrin. Biochem Pharmacol 46:1151-1157, 1993.

• 4) Ichikawa T, Ishihara K, Kusakabe T et al:Distinct effects of tetragastrin, histamine, and CCh on rat gastric mucin synthesis and contribution of NO. Am J Physiol 274:G138-G146, 1998.
  pubmed

• 5) Tanaka s, Akiba Y, Kaunitz JD:Pentagastrin gastroprotection against acid is related to H2 receptor activation but not acid secretion. Gut 43:334-341, 1998.

• 6) Kolbasa KP, Lancaster C, Olafsson AS et al:Indomethacin-induced gastric antral ulcers in hamsters. Gastroenterology 95:932-944, 1998.

• 7) Takahashi S, Okabe S:The cytoprotective effectof leminoprazole on indomethacin-induceddamage to gastric mucosal cells. J Pharmacol Ther 279:975-982, 1996.

• 8) Seibert K, Zhang Y, Leahy K et al:Pharmacological and biochemical demonstration of the role of cyclooxygenese-2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017, 1994.

• 9) Brzozowski T, Konturek PC, Konturek SJ et al:Involvemant of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiol Pharmacol 51:751-773, 2000.
  pubmed

• 10) Iseki S:Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem J 27:323-328, 1995.
  pubmed

• 11) Takeuchi K, Yagi K, Kato S et al:Roles of prostaglandin E-receptor subtypes in gastric and duodenal bicarbonate secretion in rats. Gastroenterology 113:1553-1559, 1997.
  pubmed

• 12) Masuda E, Kawano S, Nagano K et al:Endogenous nitric oxide modulates ethanol induced gastric mucosal inlury in rats. Gastroenterology 108:58-64, 1995.
  pubmed

• 13) Peskar BM, Respondek M, Muller KM et al:A role of nitric oxide in capsaicin-induced gastroprotection. Eur J Phamarcol 198:113-114, 1991.
  pubmed

• 14) Stroff T, Plate S, Respondek M et al:Protection by gastrin in the rat stomach involves afferent neurons, calcitonin gene-related peptide, and nitric oxide. Gastroenterology 109:89-97, 1995.
  pubmed

• 15) Lundberg Jo, weitzberg E, Lundberg JM et al:Intragastric nitric oxide production in humans:measurements in expelled air. Gut 35:1543-1546, 1994.
  pubmed

• 16) Wada K, Kamisaki Y, Ohkura T et al:Direct measurement of nitric oxide release in gastric mucosa during ischemia-reperfusion in rats. Am J Physiol 274:G465-G471, 1998.
  pubmed

• 17) Schmassmann A, Stettler C, Poulson R et al:Roles of hepatocyte growth factor and its receptor met during gastric ulcer healing in rats (abstr). Gastroenterology 113:1858, 1997.

• 18) Kinoshita Y, Hassan MS, Kawamura M et al:Increased hepatocyte growth factor content in rat stomach during omeprazole treatment. Digestion 59:102-109, 1998.
  pubmed

• 19) Takahashi M, Ota S, Hata Y et al:Hepatocyte growth factor as a key to modulate anti-ulceraction of prostaglandin in stomach. J Clin Invest 98:2604-2611, 1996.

• 20) Murayama Y, Miyagawa J, Higashiyama s et al:Localization of heparin-binding epidermal growth factor-like growth factor in human gastric mucosa. Gastroenterology 109:1051-1059, 1995.
  pubmed

• 21) Barnard JA, Graves-Deal R, Pittelkow MR et al:Auto-and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem 269:22817-22822, 1994.
  pubmed

• 22) Tsutsui S, Shinomura Y, Higashiyama S et al:Induction of heparin-binding epidermal growth factor-like growth factor and amphiregulin mRNAs by gastrin in the rat stomach. Biochem Biophys Res Commun 235:520-523, 1997.
  pubmed

• 23) Miyazaki Y, Shinomura Y, Tsutsui S et al:Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology 116:78-89, 1999.
  pubmed

• 24) Gibson S, Tu S, Oyer R et al:Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274:17612-17618, 1999.
  pubmed

• 25) DuBois RN, Awad J, Morrow J et al:Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Invest 93:493-498, 1994.

P.74 掲載の参考文献

• 1) Flemstrom G, Kivilaakso E:Demonstration of a pH gradient at the luminal surface of rat duodenum in vivo and its dependence on mucosal alkaline secretion. Gastroenterology 84:787-794, 1983.

• 2) Takeuchi K, Okabe S:Gastroduodenal bicarbonate secretion:Pharmacological regulation and contribution to mucosal protection. In:Regulatory Mechanisms in Gastrointestinal Function, ed by Gaginella TS, CRC Press, 1995, pp1-26.

• 3) Fandriks L, Stage L:Simultaneous measurements of gastric motility and acid-bicarbonate secretions in the anasesthetized cat. Acta Physiol Scand 128:563-573, 1986.
  pubmed

• 4) Mertz-Nielsen A, Hillingso J, Bukhave K et al:Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans. Gut 38:6-10, 1996.
  pubmed

• 5) Inada I, Satoh H:Capsaicin-sensitive sensory neurons are involved in bicarbonate secretion induced by lansoprazole, a proton pump inhibitor, in rats. Dig Dis Sci 41:785-790, 1996.
  pubmed

• 6) Guttu K, Rosok B, Gislason H et al:Gastric bicarbonate secretion, acid secretion, and mucosal blood flow during influence, of pentagastrin and omeprazole in the cat. Scand J Gastroenterol 26:431-441, 1991.
  pubmed

• 7) Fandriks L, Jonson C:Effects of acute admini-stration of omeprazole or ranitidine on basal and vagally stimulated gastric acid secretion and alkalinization of the duodenum in anaesthetized cats. Acta Physiol Scand 138:181-186, 1990.
  pubmed

• 8) Knutson L, Flemstrom G, Gustavsson S et al:HCO3-secretion in rat duodenum after treatment with omeprazole and ranitidine. Scand J Gastroenterol 122:87-90, 1987.

• 9) Takeuchi K, Konaka A, Nishilima M et al:Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats:A comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol 14:251-257, 1999.

• 10) Takeuchi K, Matsumoto J, ueshima K et al:Role of capsaicin-sensitive afferent neurons in alkaline secretory response to luminal acid in the rat duodenum. Gastroenterology 101:954-961, 1991.
  pubmed

• 11) Akiba Y, Guth PH, Engel E et al:Acid-sensing pathways of rat duodenum. Am J Physiol 277:G268-G274, 1999.
  pubmed

P.77 掲載の参考文献

• 1) ヘリコバクター・ピロリ感染の診断及び治療に関する取扱いについて. 日本讐事新報 3995:95, 2000.

• 2) Censini S, Lange C, Xiang Z et al:cag, a pathogenicity island of Helicohacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 93:14648-14653, 1996.

• 3) 三浦総一郎, 森三樹二, 鈴木秀和ほか:H. Pyloriによる胃粘膜傷害の機序. 総合臨床 46:2481-2485, 1997.
  Medical*Online

• 4) Rathbone BJ, Wyatt JI, worsley Bw et al:Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia. Gut 27:642-647, 1986.
  pubmed

• 5) Wandall JH:Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 33:617-621, 1992.
  pubmed

• 6) Suzuki H, Suzuki M, Mori M et al:Augmented levels of gastric mucosal leukocyte activation by infection with cagA gene positive-Helicobacter pylori. J Gastroenterol Hepatol 13:294-300, 1998.
  pubmed

• 7) Yoshida N, Yoshikawa T, Tanaka Y et al:A new mechanism for anti inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 10:74-81(suppl 1), 2000.

• 8) Lapenna D, de Gioia S, Ciofani G etal:Antioxidant properties of omeprazole. FEBS lett 382:189-192, 1996.
  pubmed

• 9) Aybay C, Imir T, Okur H:The effect of omeprazole on human natural killer cell activity. Gn Pharmacol 26:1413-1418, 1995.

P.82 掲載の参考文献

• 1) Martin DF, Hollander D, May, SJ et al:Difference in relapse rates of duodenal ulcer after healig with cimetidine or tripotassium dicitrato bismuthate. Lancet i:7-10, 1981.
  pubmed

• 2) Lee FI, Samloff IM, Hardman M:Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet i:1299-1302, 1985.
  pubmed

• 3) 川崎紀則, 藤岡利生:Proton pump inhibitorのH. pylori除菌作用. 治療学 28(4):371-376, 1994.

• 4) Chiba N, Rao Bv, Rademaker JW et al:Meta-analysis of the efficacy of antibiotics therapy in eradicating Helicohacter pylori. Am J Gastroenterol 187:1716-1727, 1992.

• 5) Diaz MQ, Escobar As:Metronidazole versus cimetidine in treatment of gastroduodenal ulcer. Lancet i:907, 1986.

• 6) 高橋信一, 伊藤武, 斉藤昌三:除菌療法の実際. ヘリコバクター・ピロリとその除菌法. 寺野彰, 高橋信一編, 南江堂, 東京, 1999, pp85-95.

• 7) 白井孝之, 三輪剛:Classical triple therapyの有用性. Curr Ther 4:109-114, 1996.

• 8) McNulty CAM:In:Treatment of:Camppylobacter pylori in gastritis and peptic ulcer disease. ed by Blaser MJ, Igaku-shoin, 1989, pp195-207.

• 9) Unge P, Eriksson K, Bergman B et al:Omeprazole and amoxicillin in patients with duodenal ulcer:Helicobacter pylori eradication and remission of ulcers and symptoms during a 6-month follow-up (abstr) . Gastroenterology 110:A262, 1996.

• 10) Spinzi GC, Bortolia, Colombo E et al:Dual therapy of omeprazole plus amoxicillin versus omeprazole plus clarithromycin for cure of Helicobacter pylori in ulcer patients (abstr). Gastroenterology 110:A262, 1992.

• 11) Fukuda Y, Yamamoto I, Okui M et al:Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 7(suppl 1):S45-S47, 1995.

• 12) Bazzori F, Zagari RM, Fosi S et al:Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 6:773-777, 1994.

P.84 掲載の参考文献

• 1) Wallmark B, Larsson H, Humble L:The relationship between gastric acid secretion and gastric H+/K+-ATPase activity. J Biol Chem 260:13681-13684, 1985.
  pubmed

• 2) Inada I, Satoh H:Capsaicin-sensitive sensory neurons are involved in bicarbonate secretion induced by lansoprazole, a proton pump inhibitor, in rats. Dig Dis Sci 41:785-790, 1996.
  pubmed

• 3) Yoshida N, Yoshikawa T, Tanaka Y et al:A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14(suppl 1):74-81, 2000.

• 4) Nakamura M, Yanaka A, Akiba Y et al:Auotcrine nerve surrounding esophageal mucous gland is affected by proton pump inhibitor lansoprazole:Possible relebance to bicarbonate secretion (abstr). Gastroenterology 120:A433, 2001.

• 5) 中村正彦, 秋葉保志, 井上淳ほか:十二指腸粘膜内lansoprazole結合部位に関するradioautography法による検討-十二指腸酢酸潰瘍形成時の変化-. 胃分泌研究会誌 28:55-58, 1996.

• 6) Sato N, Kawano S, Tsuji S et al:Gastric blood flow in ulcer diseases. Scand J Gastroenterol (suppl) 208:14-20, 1995.
  pubmed

• 7) Nakamura M, Oda M, Akiba Y et al:Uptake site of lansoprazole, a proton pump inhibitor, in human fundic mucosa:possible relevance with fibroblast and Helicobacter pylori. Cell Mol Biol (Noisy-le-grand) 41:125-130, 1995.
  pubmed

• 8) Tsuchida T, Tsukamoto Y, Segawa K et al:Effects of cimetidine and omeprazole on angiogenesis in granulation tissue of acetic acid-induced gastric ulcers in rats. Digestion 47:8-14, 1990.
  pubmed

• 9) Schmassmann A, Tamawski A, Peskar BM et al:Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats:interaction with indomethacin. Am J physiol 268(2pt 1):G276-G285, 1995.

• 10) 辻晋吾, 川野淳:胃粘膜微小循環の臨床. 医学のあゆみ 184:785-788, 1998.

• 11) Nakamura M, Oda M, Akiba Y et al:Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa. J Clin Gastroenterol 21 (suppl 1):S24-S29, 1995.

• 12) 秋本真寿美, 橋本洋, 柳沢明子ほか:ラット酢酸胃潰瘍の治癒過程における血管新生因子の変化, 及びProton pump Inhibitor投与による影響. 日消誌 97:A306, 2000.

P.88 掲載の参考文献

• 1) 高橋盛男, 太田慎一, 寺野彰:傷害修復と組織相関. Mehio 10:50-54, 1994.

• 2) 大林雅春, 有沢富康, 伊藤雅文ほか:ラット実験胃潰瘍における肉芽新生血管の細胞接着因子発現に関する免疫組織学的研究. 日本網内系会誌 33:217-226, 1993.

• 3) 有沢富康, 塚本純久, 後藤秀実ほか:血管内皮細胞表面抗原からみた胃潰瘍肉芽血管新生-接着分子からの検討-. Prog Med 13:489-495, 1993.
  Medical*Online

• 4) Takemoto T, Sakaki N, Tada M et al:Evaluation of peptic ulcer healing with a highly magnifying endoscope:potential prognostic and therapeutic implications. J Clin Gastroenterol 13 (suppl 1):S125-S128, 1991.

• 5) 中澤三郎, 中村常哉, 芳野純治ほか:超音波内視鏡による胃潰瘍判定の試み-胃潰瘍の新しい時相分類の確立のために-. Gastroenterol Endosc 29:1991-1997, 1987.

Part3 EBM EBMにもとづいたプロトンポンプ阻害薬の臨床的位置づけ

P.95 掲載の参考文献

• 1) Collins R, Langman M:Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trial. N Engl J Med 313:660-666, 1985.

• 2) Walt RP, Cottrell J, Mann SG et al:continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 340:1058-1062, 1992.
  pubmed

• 3) Khuroo Ms, Yattoo GN, Javid G et al:A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 336:1054-1058, 1997.
  pubmed

• 4) Daneshmend TK, Hawkey CJ, Langman MJ et al:Omeprazole versus placebo for acute upper gastrointestinal bleeding:randomised double blind controlled trial. BMJ 304:143-147, 1992.
  pubmed

• 5) Lau JY, sung JJ, Lee KK et al:Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcer. N Engl J Med 343:310-316, 2000.
  pubmed

• 6) Ohning G Soll AH:Medical treatment of peptic ulcer disease. Am Fam, Physician 39:257-270, 1989.

• 7) Howden CW, Hunt AH:The relationship between suppression of acidity and gastric ulcer healing. Aliment Pharmacol Ther 4(1)25-33, 1990.

• 8) Sato N, Kawano S, Kamada T et al:Hemodynamics of the gastric mucosa and gastric ulceration in rats and in patients with gastric ulcer. Dig Dis Sci 31:35S-41S, 1985 Hemodynamics of the gastric mucosa and gastric ulceration in rats and in patients with gastric ulcer. Dig Dis 5ci 31:35S-41S, 1985.

• 9)三好秋馬,谷内昭,後藤由夫ほか:Omeprazole の十二指腸潰瘍に対する臨床的有用性の検討.薬理と臨床 16:563-582,1988.

• 10)三好秋馬,谷内昭,後藤由夫ほか:Omeprazole の胃潰瘍に対する臨床的有用性の検討.薬理と臨床 16:543-561,1988.

• 11)竹本忠良,並木正義,後藤由夫ほか:胃潰瘍に対するLansoprazole(AG-1749)の臨床的有用性の検討.臨床成人病 21(2):327-345,1991.

• 12) Van der Hulst RW, Rauws EA, Koycu B et al:Prevention of ulcer recurrence after eradication of Helicobacter pylori:a prospective long-term follow-up study. Gastroenterology 113:1082-1086, 1992.

• 13) Walt RP:Misoprostol for the treatment of peptic ulcer and anti-inflammatory-drug-induced gastroduodenal ulceration. N Eng J Med 327:1575-1580, 1992.

• 14) Taha AS, Hudson N, Hawkey CJ et al:Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435-1439, 1996.
  pubmed

• 15) Cullen D, Bardhan KD, Eisner M et al:Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 12:135-140, 1998.
  pubmed

• 16) Hawkey CJ, Karrasch JA, Szczepanski L et al:Omeprazole compared with misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734, 1998.

• 17) Yeomans ND, Tulassay Z, Juhasz L et al:A comparison of omeprazole with ranitidine for ulcers associated with noonsteroidal antiinflammatory drugs. Acid Suppression Trial:Rantidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726, 1998.

• 18) Hawkey CJ, Tulassay Z, Szczepanski L et al:Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal antiinflammatory drugs:HELPS NSAIDs study. Helicobacter Eradication for Lesion Prevention Lancet 352:1016-1021, 1998.

• 19) 関口利和, 西岡利夫, 小暮道夫ほか:逆流性食道炎に対するシメチジンの臨床効果. Cimetidine 84, 三好秋馬編, 東京, メディカルトリビューン, 1984, pp150-156.

• 20) 岸清一郎:ヒスタミンH2受容体拮抗剤Ranitidineの逆流性食道炎に対するシメチジンの臨床的有用性の検討. ザンタック錠文献集, 東京, Excerpta Medica, 1984, pp161-169.

• 21) 関口利和, 多賀須幸男, 三輪剛ほか:逆流性食道炎に対するFamotidineの臨床効果. 臨床と新薬 20:2476-2485, 1983.

• 22) 関口利和, 常岡健二, 小林正文ほか:逆流性食道炎に対するNizatidineの臨床評価. 臨床と新薬 17 (suppl 2):457-468, 1989.

• 23) 関口利和, 西岡利夫, 草野元康ほか:逆流性食道炎に対するOmeprazoleの臨床評価. 臨床と新薬 16 (suppl 3):745-756, 1988.

• 24) 関口利和, 松崎勉, 堀越勤ほか:逆流性食道炎に対するLansoprazoleの臨床評価. Ther Res 12:191-213, 1991.
  Medical*Online

• 25) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するOmeprazoleの臨床評価 (第1報) -治療効果と安全性の検討-. 臨床医薬 15 (1):91-106, 1999.

• 26) Dent J, Yeomans ND, Mackinnon M et al:Omeprazole v ranitidine for prevention of relapse in reflux oesophgagitis. A controlled double blind trial of their efficacy and safety. Gut 35:590-598, 1994.

• 27) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するOmeprazoleの臨床評価 (第2報) -再発予防効果と安全性の検討-. 臨床医薬 16 (9) 1387-1404, 2000.

• 28) 遠藤光夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749の臨床的有用性の検討-第二報維持効果の検討-. 臨床成人病 29:959-977, 1999.

• 29) 岸田泰弘, 湯川永洋:Zollinger-Ellison症候群に対するOmeprazoleの使用経験. 薬理と臨床 16 (suppl 3) 727-733, 1988.

• 30) Metz DC, Strader DB, Orbuch M et al:Use of omeprazole in Zollinger-Ellison syndrome:a prospective nine-year srudy of efficacy and safety. Aliment Pharmacol Ther 7:597-610, 1993.

P.102 掲載の参考文献

• 1) Annibale B, D'Ambra G, Luzzi I et al:Dose pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Am J Gastroenterol 92:790-794, 1997.

• 2) 金丸光隆, 中島光好, 梶保徳明ほか:プロトンポンプ阻害剤Omeprazoleの胃液抑制作用-健康成人での基礎分泌および刺激分泌抑制作用について-. 臨床医薬 5:13-28, 1989.

• 3) 三好秋馬, 松尾裕, 泉原弥太郎ほか:プロトンポンプ阻害剤Omeprazoleの胃酸分泌抑制に関する研究-夜間分泌抑制作用についての検討-. 薬理と治療 16 (suppl 3):479-492, 1988.

• 4) 三好秋馬, 中島光好, 谷内昭ほか:消化性潰瘍に対するOmeprazoleの臨床的研究-Pilot study成績-. 薬理と治療 16 (suppl 3):505-516, 1988.

• 5) HUttemann W, Rohner HG, du Bosque G et al:20 versus 30mg omeprazole once daily:Effect on healing rates in 115 doudenal ulcer patients. Digestion 33:117-120, 1986.

• 6) 三好秋馬, 中島光好, 谷内昭ほか:胃潰瘍・十二指腸潰瘍におけるOmeprazoleの用量検索二重盲検試験. 薬理と治療 16 (suppl 3):517-541, 1988.

• 7) 中澤三郎, 塚本純久, 伊藤圓ほか:胃潰瘍・十二指腸潰瘍に対するOmepazoleの臨床的有用性の検討-多施設協同研究-. 薬理と治療 16 (suppl 3):679-690, 1988.

• 8) 三好秋馬, 谷内昭, 後藤由夫ほか:Omeprazoleの胃潰瘍に対する臨床的有用性の検討-多施設二重盲検法によるFamotidineとの比較. -薬理と治療 16 (suppl 3):543-561, 1988.

• 9) 三好秋馬, 谷内昭, 後藤由夫ほか:Omeprazoleの十二指腸潰瘍に対する臨床的有用性の検討-多施設二重盲検法によるFamotidineとの比較. -薬理と治療 16 (suppl 3):563-582, 1988.

• 10) 竹本忠良, 岡崎幸紀, 多田正弘ほか:胃潰瘍・十二指腸潰瘍に対するLansoprazole (AG-1749)の臨床的有用性の検討-前期臨床第II相試験-. 臨床成人病 21:761-783, 1991.

• 11) 竹本忠良, 並木正義, 後藤由夫ほか:胃潰瘍・十二指腸潰瘍に対するLansoprazole (AG-1749)の臨床的有用性の検討-用量および投与時期の検討-. 臨床成人病 21:995-1013, 1991.

• 12) 竹本忠良, 並木正義, 後藤由夫ほか:胃潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討-多施設二重盲検法によるFamotidineとの比較-. 臨床成人病 21:327-345, 1991.

• 13) 竹本忠良, 並木正義, 後藤由夫ほか:十二指腸潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討-多施設二重盲検法によるFamotidineとの比較-. 臨床成人病 21:613-631, 1991.

• 14) 中澤三郎, 芳野純治, 山近仁ほか:胃潰瘍・十二指腸潰瘍に対するE3810の臨床的有用性の検討-前期臨床第II相試験 (パイロット試験)-. Modern Physician 14:1-22, 1994.

• 15) 中澤三郎, 並木正義, 松尾裕ほか:E3810の胃潰瘍・十二指腸潰瘍に対する後期臨床第U相試験-二重盲検比較試験による至適用量の検討-. Modern Physician 14:38-68, 1994.

• 16) 大原秀一, 金原孝行, 関根仁ほか:オメプラゾールの朝食前と朝食後投与の胃酸分泌抑制効果の比較. 薬理と治療 23:879-885, 1995.
  Medical*Online

• 17) 三好秋馬, 荒井泰道, 中澤三郎ほか:吻合部潰瘍に対するOmeprazoleの臨床評価. 薬理と治療 16 (suppl 3):691-700, 1988.

• 18) 竹本忠良, 早川滉, 野村喜重郎ほか:吻合部潰瘍に対するLansoprazoleの有用性の検討. Moderm Physician 11:253-260, 1991.

• 19) 湯川永洋, 湯川研一:Lansoprazoleの吻合部潰瘍に対する有用性の検討. 薬理と治療 18:4919-4924, 1990.
  Medical*Online

• 20) 中川充文, 大内敏弘, 今村康彦ほか:吻合部潰瘍に対するE3810の臨床的有用性の検討. Modern Physician 14:100-107, 1994.

• 21) 吉田豊, 棟方昭博, 高杉滝夫ほか:吻合部潰瘍に対するE3810の臨床評価. Modern Physician 14:108-115, 1994.

• 22) Allende HD, Bissonnette BM, Raufman JP et al:Progressive increase in drug requirement in the long-tern medical management of patients with Zollinger-Ellison syndrome. Gastroenterology 82:1007, 1982.

• 23) Meijer JL, Jansen JB, Lamers CB et al:Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcer. Digestion 44 (suppl 1):31-39, 1989.

• 24) Jansen RT, Fraker DL:Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrioma. JAMA 271:1429-1435, 1994.

• 25) 高石雅章, 小林健介, 水野嘉夫:プロトンポンプ阻害剤が有効であったZollinger-Ellison症候群の1例. 治療学 28:441-445, 1994.

• 26) 園田孝志, 筒井信一, 末廣剛敏ほか:AG-1749投与が有効であったZollinger-Ellison症候群の1例. 薬理と治療 18:4911-4918, 1990.
  Medical*Online

• 27) 非ステロイド性抗炎症剤による上部消化管障害に関する疫学調査. リウマチ 31:98-111, 1991.

• 28) Yaomans ND, Tulassay Z, Juhasz L et al:A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial:Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726, 1998.

• 29) Hawkey qr, Karrasch JA, szczepanski L et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734, 1998.

• 30) 森治樹, 高橋春樹, 岡野晃ほか:Omeprazole注射剤の臨床薬理試験-胃液分泌抑制効果-. 薬理と治療 23 (suppl):2097-2105, 1995.

• 31) 三好秋馬, 豊田隆謙, 浅木茂ほか:Omeprazole注射剤の24時間胃内pHに関する研究-単回投与試験-. 薬理と治療 23 (suppl):2107-2116, 1995.

• 32) 三好秋馬, 青木照明, 松尾裕ほか:上部消化管出血に対するOmeprazole注射剤の臨床的研究-Pilot Study-. 薬理と治療 23 (suppl):2125-35, 1995.

• 33) 三好秋馬, 青木照明, 中島光好ほか:上部消化管出血に対するOmeprazole注射剤の臨床的研究-用量検索二重盲検試験 . 薬理と治療 23 (suppl):2137-52, 1995.

• 34) 三好秋馬, 青木照明, 中島光好ほか:上部消化管出血に対するOmeprazole注射剤の臨床的研究-Famotidine注射剤を対照薬とした二重盲検試験-. 薬理と治療 23 (suppl):1593-1607, 1995.

• 35) 佐藤貴一, 滝本拓哉, 木平健ほか:消化性潰瘍とHelicobacter. pylori除菌療法のすべて Dual therapy (二剤併用療法). Med Pract 13:1901-1910, 1996.

• 36) Pipkin GA, Dixon JS, Williamson R et al:Clarithromycin dual therapy regimens for eradication of Helicobacter pylori:a review. Helicobacter 2:159-171, 1997.
  pubmed

• 37) Kawano S, Murakami M, Saita H et al:Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. J Gastroenterol 31 (suppl 9):41-43, 1996.
  pubmed

• 38) 木村健, 浅香正博, 豊田隆謙ほか:Lansoprazole/amoxicillin 2剤併用によるHelicobacter pylori除菌療法の全国多施設第2相試験. 第4回ヘリコバクター学会抄録集, 1998, p73.

• 39) Lind T, Veldhuyzen van Zanten S, Unge P et al:Eradication of Helicohacter pylori using one-week triple therapies combining omeprazole with two antimicrobials:the MACH-I Study. Helicobacter 1:138-144, 1996.

• 40) Lamouliatte H, Cayla R, Zerbib F et al:Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradication Helicobacter pylori infection:results of aprospective randomized open study. Am J Gastroenterol 93:1531-1534, 1998.

• 41) Moayyedi P, Langworthy H, Shanahan K et al:Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. Helicobacter 1:71-74, 1996.
  pubmed

• 42) 浅香正博, 杉山敏郎, 佐藤貴一ほか:除菌ガイドライン関連報告Helicobacter pylori陽性消化性潰瘍に対するLANIAM/CAM 3剤併用除菌療法の第III相二重盲検試験. 第6回日本ヘリコバクター学会学術集会抄録集, 2000, pp90.

• 43) Hokari K, Sugiyama T, Kato M et al:Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. . Aliment Pharmacol Ther 15:1479-1484, 2001.
  pubmed

• 44) 岸清一郎, 辻泰弘, 伊東進ほか:逆流性食道炎に対するOmeprazoleの臨床的有用性の検討. 薬理と治療 16 (suppl 3):757-765, 1988.

• 45) 関口利和, 西岡利夫, 草野元康ほか:逆流性食道炎に対するOmeprazoleの臨床評価. 薬理と治療 16 (suppl 3):745-756, 1988.

• 46) 岸清一郎, 伊東進, 梶本宜史ほか:逆流性食道炎に対するLansoprazoleの臨床的有用性の検討. Prog-Med 1O:3197-3206, 1990.

• 47) 関口利和, 松崎勉, 堀越勤ほか:逆流性食道炎に対するLansoprazoleの臨床評価. Ther Res 12:191-212, 1991.
  Medical*Online

• 48) 谷内昭, 矢花剛, 得地茂ほか:逆流性食道炎に対するE3810の臨床評価. Modern Physician 14:124-136, 1994.

• 49) 中野哲, 高山哲夫, 大木早人ほか:逆流性食道炎に対するプロトンポンプ阻害剤, E3810の臨床評価. Modern Physician 14:116-123, 1994.

• 50) Furukawa N, Iwakiri R, Koyama T et al:Proportion of reflux esophagitis in 6010 Japanese adults:prospective evaluation by endoscopy. J Gastroenterol 34:441-444, 1999.
  pubmed

• 51) Havelund T, Laursen LS, Lauritsen K:Efficacy of omeprazole in lower grades of gastro-esophageal reflux disease. Scand J Gastroenterol 29 (suppl 201):69-73, 1994.

• 52) Chiba N, De Gara CJ, Wilkinson JM et al:speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease:a meta-analysis. Gastroenterology 112:1798-1810, 1997.
  pubmed

• 53) 遠藤光夫, 関口利和, 中村孝司ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749の臨床的有用性の検討-第一報治療効果の検討 . 臨床成人病 29:805-817, 1999.

• 54) Feldman M, Harford W V, Fisher RS et al:Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K+-ATPase inhibitor:a controlled, double-blind study. Am J Gastroenterol 88:1212-1217, 1993.

• 55) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するOmeprazoleの臨床評価-再発予防効果と安全性の検討-. 臨床医薬 16:1387-1404, 2000.

• 56) 遠藤光夫, 関口利和, 中村孝司ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749の臨床的有用性の検討-第二報維持効果の検討-. 臨床成人病 29:959-977, 1999.

• 57) Carlsson R, Galmiche Jp, Dent J et al:Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs:a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 11:473-482, 1997.

• 58) Robinson M, Lanza F, Avner D et al:Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double blind, placebo-controlled trial. Ann Intern Med 124:859-867, 1996.
  pubmed

P.109 掲載の参考文献

• 1) Bianchi Porro G, Corinaldesi R, Lazzaroni M et al:Long term treatment with omeprazole 20mg three days a week or 10mg daily in the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 8:541-548, 1994.

• 2) Lauritsen K, Andersen BN, Laursen LS et al:Omeprazole 20mg three days a week and 10mg daily in prevention of duodenal ulcer relapse. Double-blind comparative trial. Gastroenterology 100:663-669, 1991.

• 3) 岩崎有良:長期維持療法の意義. 臨床消化器内科 9:1107-1119, 1994.

• 4) 中村孝司:プロトンポンプインヒビター. 日本消化性潰瘍学, 竹本忠良監修, 中澤三郎, 本賀本幸, 岡崎幸紀編, 医科学出版社, 東京, 1995, pp867-890.

• 5) 矢花剛, 落合亨:潰瘍の再発予防とPPIによる維持療法-とくにweekend therapyに関して. 医学のあゆみ 159:787-790, 1991.

• 6) Hoshino E, umeda N, Sano J et al:Lansoprazole for maintenance therapy of peptic ulcer disease:weekend full-dose or every day half-dose administration? J Clin Gastroenterol 20 (suppl 2):S72-S74, 1995.
  pubmed

• 7) Chen SP, Bei L, Wen SH:Study on omeprazole 20mg twice weekly in prevention of duodenal ulcer relapse. Zhonghua Ner Ke Za Zhi 32:538-541, 1993.

• 8) Catalano F, Liberti A, Branciforte G et al:Twelve-month omeprazole vs ranitidine in the treatment of Heltcobacter pylori positive patients with healed duodenal ulcer. Ital J Gastroenterol 27:21-25, 1995.
  pubmed

• 9) Hawkey q, Karrasch JA, Szczepanski L et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734, 1998.

• 10) Yeomans ND, Tulassay z, Juhasz L et al:A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial:Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726, 1998.

• 11) Leandro G, Pilotto A, Franceschi M et al:The Prevention of acute NSAID-related gastroduodenal damage:ameta-analysis of controlled clinical trials. Dig Dis Sci 46:1924-1936, 2001.

• 12) Rostom A, Wells G, Tugwell P et al:The prevention of chronic NSAID induced upper gastrointestinal toxicity:Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 27:2203-2214, 2000.
  pubmed

• 13) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するOmeprazoleの臨床評価 (第2報) 再発予防効果と安全性の検討. 臨床医薬 16:1387-1404, 2000.

• 14) 遠藤光夫, 関口利和, 中村孝司ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749の臨床的有用性の検討 (第2報) 維持療法の検討. 臨床成人病 29:959-977, 1999.

• 15) Dent J:Australian clinical trials of omeprazole in the manegement of reflux oesophagitis. Digestion 47 (suppl 1):69-71, 1990.

• 16) Isal J, Zeitoun P, Barbier P et al:comparison of two dosage regimens of omeprazole-10mg once daily and 20mg weekends-as prophylaxis against recurrence of reflux esophagitis (abstr). Gastroenterology 98:A63, 1990.

P.113 掲載の参考文献

• 1) Labenz J, Blum AL, Bayerdorffer E et al:curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112:1442-1447, 1997.
  pubmed

• 2) Asaka M, Kato M, Kudo M et al:Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging:studies in asymptomatic Japanese adults. Helicobacter 1:52-56, 1996.
  pubmed

• 3) Maekawa T, Kinoshita Y, Okada A et al:Relationship between severity and symptoms of reflux esophagitis in elderly patients in Japan. J Gastroenterol Hepatol 13:927-930, 1998.
  pubmed

• 4) Furukawa N, Iwakiri R, Koyama T et al:Proportion of reflux esophagitis in 6,010 Japanese adults:prospective evaluation by endoscopy. J Gastroenterol 34:441-444, 1999.

• 5) Armstrong D, Bennett JR, Blum AL et al:The endoscopic assessment of esophagitis:a progress report on observer agreement. Gastroenterology 111:85-92, 1996.
  pubmed

• 6) Vigneri S, Termini R, Leandro G et al:A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333:1106-1110, 1995.

• 7) DeVault KR, Castell DO:Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 155:2165-2173, 1995.
  pubmed

• 8) Dent J, Brun J, Fendrick AM et al:An evidence-baced appraisal of reflux disease management-The Genval workshop report. Gut 44:S1-S6, 1999.

• 9) 本郷道夫:GERDガイドライン. Ther Res 20:429-440, 1999.

• 10) Wesdorp IC, Dekker W, Festen HP:Efficacy of famotidine 20mg twice a day versus 40mg twice a day in treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci 38:2287-2293, 1993.
  pubmed

• 11) Simon TJ, Berenson MM, Berlin RG et al:Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive esophagitis. Aliment Pharmacol Ther 8:71-79, 1994.

• 12) Bardhan KD, Hawkey CJ, Long RG et al:Lansoprazole versus ranitidine for the treatment of reflux esophagitis. UK lansoprazole Clinical Research Group. Aliment Pharmacol Ther 9:145-151, 1995.
  pubmed

• 13) Ducrotte P, Guillemot F, Elouaer-Blanc L et al:Comparison of omeprazole and famotidine on esophageal pH in patients with moderate or severe esophagitis:a cross-over study. Am J Gastroenterol 89:717-721, 1994.
  pubmed

• 14) Soga T, Matsuura M, Kodama Y et al:Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?J Gastroenterol 3:435-440, 1999.
  pubmed

• 15) Chiba N, DeGara CJ, Wilkinson JM et al:Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease:a meta-analysis. Gastroenterology 112:1798-1810, 1997.

• 16) Harris RA, Kuppermann M, Richter JE:Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrence of erosive reflux esophagitis:a cost-effectiveness analysis. Am J Gastroenterol 192:2179-2187, 1997.

P.120 掲載の参考文献

• 1) Huang JQ, Sridhar s, Hunt RH:Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease:a meta-analysis. Lancet 359:14-22, 2002.
  pubmed

• 2) Eriksson S, Langstrom G, Rikner L et al:Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis:a meta-analysis. Eur J Gastroenterol Hepatol 7:467-475, 1995.
  pubmed

• 3) Walan A, Bader JP, Classen M et al:Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320:69-75, 1989.
  pubmed

• 4) Classen M, Dammann HG, Domschke W et al:Abheilungsraten nach Omeprazol-und Ranitidine-Behandlung des Ulcus ventriculi, Dtsch Med Wochenschr 110:628-633, 1985.
  pubmed

• 5) Barbara L, saggioro A, olsson J et al:Omeprazole 20 mg om and ranitidine 150 mg bd in the healing of benign gastric ulcers-an Italian multicentre study (abstr). Gut 28:A1341, 1987.

• 6) Bate CM, Wilkinson SP, Bradby GV et al:Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut 30:1323-1328, 1989.
  pubmed

• 7) Tunis SR, Sheinhait IA, Schmid CH et al:Lansoprazole compared with histamine 2-receptor antagonists in healing gastric ulcers:a meta-analysis. Clin Mer 19:743-757, 1997.

• 8) Cloud ML, Enas N, Humphries TJ et al:Rabeprazole in treatment of acid peptic diseases:result of thrce placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 43:993-1000, 1998.

• 9) Dekkers CPM, Beker JA, Thjodleifsson B et al:Comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of active gastric ulcer-a European multicentre study. Aliment Pharmacol Ther 12:789-795, 1998.

• 10) Lanza F, Bardhan KD, Perdomo C et al:Efficacy of rabeprazole once daily for acid-related disorders. Dig Dis Sci 46:587-596, 2001.
  pubmed

• 11) Florent C, Audigier JC, Boyer J et al:Efficacy and safety of lansoprazole in the treatment of gastric ulcer:a multicentre study. Eur J Gastroenterol Hepatol 6:1135-1139, 1994.

• 12) Stedman CAM, Barclay ML:Review article. Comparison of the pharmacokinetics, acidsuppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963-978, 2000.

• 13) 三好秋馬, 谷内昭, 後藤由夫ほか:Omeprazoleの胃潰瘍に対する臨床的有用性の検討-多施設二重貢献によるFamotidineとの比較. 薬理と治療 16 (suppl 3):543-561, 1988.

• 14) 竹本忠良, 並木正義, 後藤由夫ほか:胃潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討-多施設二重盲検法によるFamotidineとの比較. 臨床成人病 21:327-345, 1991.

• 15) 中澤三郎, 並木正義, 松尾裕ほか:胃潰瘍に対するE3810の臨床的有用性の検討-多施設二重盲検によるFamotidineとの比較. Clin Eval 21:337-359, 1993.

• 16) 三好秋馬, 中島光好, 谷内昭ほか:胃潰瘍・十二指腸潰瘍におけるOmeprazoleの用量検索二重盲検試験. 薬理と治療 16 (suppl 3):517-541, 1988.

• 17) 竹本忠良, 岡崎幸紀, 多田正弘ほか:胃潰瘍・十二指腸潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討-前期臨床第II相試験. 臨床成人病21:769-783, 1991.

• 18) 竹本忠良, 並木正義, 後藤由夫ほか:胃潰瘍・十二指腸潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討-Lansoprazoleの2用量とファモチジンとの比較. 臨床成人病 21:743-767, 1991.

• 19) 中澤三郎, 芳野純治, 山近仁ほか:胃潰瘍・十二指腸潰瘍に対するE3810の臨床的有用性の検討-前期臨床第II相試験 (パイロット試験). Modern Physician 14:1-22, 1994.

• 20) 中澤三郎, 並木正義, 松尾裕ほか:E3810の胃潰瘍・十二指腸潰瘍に対する後期第II相試験-二重盲検比較試験による至適用量の検討. Modern Physician 14:38-68, 1994.

• 21) 中村孝司:プロトンポンプ阻害薬 (PPI)-EBM からみたその有用性と適応. H. pylori除菌時代の消化性潰瘍の治療. 中村孝司編, 日本メディカルセンター, 東京, 2000, pp176-183.

• 22) 浅木茂, 浅香正博, 藤野雅之ほか:NSAIDs投与RA患者の胃潰瘍. 消化器内視鏡 5:497-504, 1993

• 23) Wolfe MM, Lichtenstein DR, Singh G:Gastro-intestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899, 1999
  pubmed

• 24) Tildesley G, Ehsanullah Rs, wood JR:Ranitidine in the treatment of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drugs. Br J Rheumatol 32:474-478, 1993
  pubmed

• 25) Jaszewski R, Graham DY, Stromatt SC:Treatment of nosteroidal antiinflammatory drug-induced gastric ulcers with misoprostol. A double-blind multicenter study. Dig Dis Sci 37:1820-1824, 1992

• 26) Lancaster-smith MJ, Jaderberg ME, Jackson DA:Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 32:252-255, 1991
  pubmed

• 27) Malchow-Moller A:Treatment of peptic ulcer induced by non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 22 (suppl 127):87-91, 1987

• 28) Hudson N, Taha AS, Russell RI et al:Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 112:1817-1822, 1997
  pubmed

• 29) Sontag SJ, Schnell TG, Budiman-Mak E et al:Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil). Am J Gastroenterol 89:1014-1020, 1994
  pubmed

• 30) Roth S, Agrawal N, Mahowald M et al:Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 149:775-779, 1989
  pubmed

• 31) Wu CS, Wang SH, Chen PC et al:Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy? Int J Clin Pract 52:472-474, 1998
  pubmed

• 32) Hawkey Cj, Karrasch JA, Szczepanski L et al:Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAIDs-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727-734, 1998

• 33) Yeomans ND, Tulassay Z, Juhasz L et al:A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial:Ranitidine versus Omeprazole for NSAIDs-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719-726, 1998

• 34) Agrawal NM, Campbell DR, Safdi MA et al:Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers:results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 160:1455-1461, 2000

P.124 掲載の参考文献

• 1) Oi M, Ito Y, Kumagai F et al:Apossible dual control mechanism in the origin of peptic ulcer-a study on ulcer location as affected by mucosa and musculature. Gastroenterology 57:280-293, 1969

• 2) Lee YT, Sung JJ, Choi CL et al:Ulcer recurrence after gastric surgery:Is Helicobacter pylori the culprit? Am J Gastroenterol 93:928-931, 1998
  pubmed

• 3) Leivonen MK, Haglund CH, Nordling SF:Helicobacter pylori infection after partial gastrectomy for peptic ulcer and its role inrelapsing disease. Eur J Gastroenterol Hepatol 9:371-374, 1997
  pubmed

• 4) Tomititchong P, Onda M, Matsukura N et al:Helicobacter pylori infection in the remnant stomach after gastrectomy:with specialreference to the difference between Billroth I and II anastomoses. J Clin Gastroenterol 27 (suppl 1):S154-S158, 1998

• 5) Schilling D, Jakobs R, Peitz u et al:Diagnostic accuracy of ??C-urea breath test in the diagnosis of Helicobacter pylori infection in patients with partial gastric resection due to peptic ulcerdisease. Digestion 63:8-13, 2001

• 6) 大井実:吻合部潰瘍の発生. 消化性潰瘍の発生と二重規制学説, 南江堂, 東京, 1976, pp277-287

• 7) Kosunen TU, Seppala K, Sarna S et al:Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 339:893-895, 1992
  pubmed

• 8) Cutler AF, Prasad VM:Long-term follow-up of Helicobacter pylori serology after successful eradication. Am J Gastroenterol 91:85-88, 1996
  pubmed

• 9) 0hkura R, Miwa H, Murai T et al:Usefulness of a novel enzyme immunoassay for the detection of Helicobacter pylori in feces. Scand J Gastroenterol 35:49-53, 2000

• 10) Trevisani L, Sartori S, Galvani F et al:Evaluation of a new enzyme immunoassay for detecting Helicobacter pylori in feces:a prospective pilot study. Am J Gastroenterol 94:1830-1833, 1999
  pubmed

P.127 掲載の参考文献

• 1) Gustavsson S, Adami HO, Loof L et al:Rapid healing of duodenal ulcers with omeprazole:double-blind dose-comparative trial. Lancet ii:124-125, 1983

• 2) Omeprazole in duodenal ulceration:acid inhibition, symptom relief, endoscopic healing, and recurrence. Cooperative study. Br Med J (Clin Res Ed) 289:525-528, 1984
  pubmed

• 3) Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. A Scandinavian Multicentre Study. Scand J Gastroenterol 19:882-884, 1984

• 4) Prichard PJ, Rubinstein D, Jones DB et al:Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers. Br Med J (Clin Res Ed) 290:601-603, 1985
  pubmed

• 5) Naesdal J, Lind T, Bergsaker-Aspoy J et al:The rate of healing of duodenal ulcers during omeprazole treatrnent. Scand J Gastroenterol 20:691-695, 1985

• 6) Baker J-P, Modigliani R, soule JC et al:An open trial of omeprazole on short-term treatment of duodenal ulcer. Scand J Gastroenterol Suppl 118:177-178, 1986

• 7) Huttemann W, Rohner HG, duBosque G et al 20 versus 30 mg omeprazole once daily:effect on healing rates in 115 duodenal ulcer patients. Digestion 33:117-120, 1986
  pubmed

• 8) Belgian Multicentre Group:Rate of duodenal ulcer healing during treatment with omeprazole:a double blind comparison of a daily dose of 30mg versus 60mg. Scand J Gastroenterol Suppl 118:177-178, 1986

• 9) Karvonen AL, Keyrilainen O, Uusitalo A et al:Effects of omeprazole in duodenal ulcer patients. Scand J Gastroenterol 21:449-454, 1986
  pubmed

• 10) Rinetti M, Vezzadini P, Jonsson E et al:Effect and tolerability of omeprazole in the treatment of duodenal ulcer disease. Drugs Exp Clin Res 12:701-705, 1986
  pubmed

• 11) Graham DY, McCullough A, Sklar M et al:Omeprazole versus placebo in duodenal ulcerhealing. The United States experience. Dig Dis Sci 35:66-72, 1990

• 12) Lauritsen K, Andersen BN, Havelund T et al:Effect of 10 mg and 20 mg omeprazole daily onduodenal ulcer.:double blind comparative trial. Aliment Pharmacol Ther 3:59-67, 1989
  pubmed

• 13) Maton PN:Omeprazole. N Engl J Med 324:965-975, 1991
  pubmed

• 14) Calmers TC, Buyse ME:Meta-analysis. In:Data analysis for clinical medicine, the quantitative approach to patient care in gastroenterology, ed by Chamers TC, Rome International University Press, 1988, pp75-84

• 15) Tytgat GN, Lamers CB, Hameeteman W et al:Omeprazole in peptic ulcers resistant ro histamin H2-receptor antagonists. Aliment Pharmacol Ther 1:31-38, 1987

• 16) Brunner G, Creutzfeldt W, Harke U et al:Therapy with omeprazole in patients with pepti culcerations resistant to extended high-dose ranitidine treatment. Digestion 39:80-90, 1988

• 17) Brunner G, Creutzfeldt W:Omeprazole in thelong-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastrooenterol Suppl 166:101-105, 1989

• 18) Guerreiro As, Neves Bc, Quina MG:Omeprazole in the treatment of peptic ulcersresistant to H2-receptor antagonists. Aliment Pharmacol Ther 4:309-313, 1990
  pubmed

• 19) Delchier Jc, Isal JP, Eriksson s et al:Double blind multicentre comparison of omeprazole 20mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut 30:1173-1178, 1989
  pubmed

• 20) Lauritsen K, Rune SJ, Bytzer P et al:Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med 312:958-961, 1985

• 21) Bardhan KD, Bianchi Porro G, Bose K et al:A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol 8:408-413, 1986

• 22) Dahlgren S, Domellof L, Hradsky M et al:The effects of omeprazole and cimetidine on duodenalulcer healing and the relief of symptoms. Aliment Pharmacol Ther 2:483-492, 1988

• 23) 三好秋馬, 中島光好, 谷内昭ほか:胃潰瘍・十二指腸潰瘍におけるOmeprazoleの用量検索二重盲検試験. 薬理と治療 16 (suppl):3517-3541, 1998

• 24) 三好秋馬, 谷内昭, 中島光好ほか:Omeprazoleの十二指腸潰瘍に対する臨床的有用性の検討. 多施設二重盲検法によるFamotidineとの比較. 薬理と治療 16:563-582, 1988
  Medical*Online

• 25) Poynard T, Lemaire M, Agostini H:Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 7:661-665, 1995
  pubmed

• 26) 竹本忠良, 並木正義, 後藤由夫ほか:十二指腸潰瘍に対するLansoprazole (AG-1749) の臨床的有用性の検討. 多施設二重盲検法によるFamotidineとの比較. 臨床成人病 21:613-631, 1991

• 27) Breiter JR, Riff D, Humphries TJ:Rabeprazole issuperior to ranitidine in the management of active duodenal ulcer disease:results of a double-blind, randomized North American study. Am J Gastroenterol 95:936-942, 2000

P.133 掲載の参考文献

• 1) Green FW Jr, Kaplan MM, Curtis LE et al:Effect of acid and pepsin on blood coagulation and platelet aggregation. Gastroenterology 74:38-43, 1978
  pubmed

• 2) Selby NM, Kubba AK, Hawkey CJ:Acid suppression in peptic ulcer haemorrhage:a"meta-analysis". Aliment Pharmacol Ther 14:1119-1126, 2000
  pubmed

• 3) 齋藤壽仁, 大塚洋子, 平川順子ほか:各種PPIの投与初期における胃内pHの変動. 胃分泌研究会誌 32:9-12, 2000

• 4) Labenz J, Peitz U, Leusing C et al:Efficacy of primid infusions with high dose ranitidine and omeprazole to Inaintain high intragastric pH in patients with peptic ulcer bleeding:a prospective randomized controlled study. Gut 40:36-41, 1997

• 5) Lanas A, Artal A, Blas JM et al:Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol 21:103-106, 1995
  pubmed

• 6) 三好秋馬, 青木照明, 中島光好ほか:上部消化管出血に対するomeprazole注射剤の臨床的研究-famotidine注射剤を対照薬とした二重盲検比較試験-. 薬理と治療 23 (suppl):S1593-S1608, 1995

• 7) 鎌田武信, 杉山貢, 竹本忠良ほか:上部消化管出血に対するlansoprazole (AG-1749) 注射剤の第III相試験-famotidine注射剤を対照薬とした二重盲検比較試験-. 臨床成人病 12:1813-1833, 1996

• 8) Garcia Rodriguez LAG, Ruigomez A:Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epideemiology 10:228-232, 1999

• 9) Lin HJ, Lo WC, Lee FY et al:A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Lntern Med 158:54-58, 1998
  pubmed

P.139 掲載の参考文献

• 1) Gibril F, Jensen RT:Pancreatic endocrine tumors:recent insights. Clin Perspect Gastroenterol 4:19-29, 2001

• 2) Qureshi W, Rashid S:Zollinger-Ellison syndrome. Improved treatment options for this complex disorder. Postgrad Med 104:155-153, 163-164, 1998

• 3) Maton PN:Zolinger-Ellison syndrome. recognition and management of acid hypersecretion. Drugs 52:33-44, 1996

• 4) Metz DC, Strader DB, Orbuch M et al:Use of omeprazole in Zollinger-Ellison syndrome:a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 7:597-610, 1993
  pubmed

• 5) Metz Dc, Pisegna JR, Ringham GL et al:Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 38:245-256, 1993
  pubmed

• 6) Termanini B, Gibril F, Stewart CA et al:A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Aliment Parmacol Ther 10:61-71, 1996

• 7) Lew EA, Pisegra JR, starr JA et al:Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with in Zollinger-Ellison syndrome. Gastroenterology 118:696-704, 2000

• 8) Vinayek R, Frucht H, London JF et al:Intravenousomeprazole in patients with in Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 99:10, 1990

• 9) Metz DC, Pisegna JR, Fishbeyn VA et al:control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg 17:408-480, 1993

• 10) Hurliman S, Abbuhl B, Inauen W et al:Comparison of acid inhibition by either oral highdose ranitidine or omeprazole. Aliment Pharmacol Ther 8:193-201, 1994
  pubmed

• 11) Metz DC, Pisegna JR, Fishbeyn VA et al:Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 103:1498-1508, 1992
  pubmed

• 12) Hirschowitz BI, Mohnen J, Shaw S:Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrolne. Aliment Pharmacol Ther 10:507-522, 1996
  pubmed

• 13) Cadiot G, Lehy T, Ruszniewski P et al:Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment. Dig Dis Sci 38:1307-1317, 1993
  pubmed

• 14) Klinkenberg-Knol EC, Nelis F, Dent J et al:Long-term omeprazole treatment in resistant gastroesophageal reflux disease:efficacy, safety, and influence on gastric mucosa. Gastroenterology 118:661-669, 2000

• 15) Weber HC, Venzon DJ, Jensen RT et al:Studies onthe interrelation between Zolinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology 112:84-91, 1997

• 16) Watanabe T, Matsushima Y, Nakase H et al:Effects of Helicohacter pylori infection on Zollinger-Ellison syndrome. J Gastroenterol 35:735-741, 2000

• 17) Hirschowitz BI, Haber MM:Helicobacter pylori effects on gastritis, gastrin and enterochromaffin like cell in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Parmacol Ther 15:87-103, 2001

• 18) Stewart CA, Termanini B, Gibril F et al:Prospective study of the effect of long-term gastric acid anti-secretary treatment on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome (abstr). Gastroenterology 108:A226, 1995

• 19) Stewart CA, Termanini B, Sutliff VE et al:Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 12:83-98, 1998
  pubmed

• 20) Pisegna JR:The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. Curr Gastroenterol Rep 1:511-517, 1999
  pubmed

• 21) Maton PN:Review article:the management of Zollinger-Ellison syndrome. Aliment Pharmacol Ther 7:407-475, 1993

• 22) Norton JA, Fraker DL, Alexander HR et al:Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341:635-644, 1999
  pubmed

• 23) 木下芳一, 佐藤秀一, 内田靖:膵内分泌腫瘍. 臨床と研究 78:1665-1670, 2001

P.144 掲載の参考文献

• 1) 亀山仁一, 佐々木巌, 今村幹雄ほか:消化器手術後の多臓器障害 (MOF) の病態と治療-MOFとしての術後消化管出血. 外科診療 25:44-50, 1983

• 2) 亀山仁一, 八木聡, 塚本長:H2-ブロッカーの外科治療における役割, The Latest Therapyシリーズ5:胃・十二指腸潰瘍の外科治療, 白鳥常男編, 医学教育出版社, 東京, 1986, pp259-269

• 3) Nishina M, Kameyama J, Yagi s et al:Experimental studies on prevention of acute gastric ulcer in renal impairment. Experimental Ulcer 12:214-216, 1986

• 4) Suzuki Y, Kameyama J, Nishina M et al:Pathogenesis of water-immersion stress-induced gastric ulcers in rats with renal failure. Scand J Gastroenterol Suppl 162:127-130, 1989
  pubmed

• 5) 青木照明, 渡部洋三, 北島政樹ほか:手術侵襲ストレスによる胃酸分泌亢進に対するOmeprazole注射剤の抑制効果-用量検討試験-. 薬理と治療 23 (suppl 8):139-155, 1995

• 6) 青木照明, 渡部洋三, 北島政樹ほか:術後胃酸分泌亢進に対するOmeprazole注射剤の抑制効果-塩酸ピレンゼピンとの二重盲検比較試験-. 薬理と治療 23 (suppl 8):157-173, 1995

• 7) 浅原利正, 岡島正純, 正岡良之ほか:手術侵襲ストレスによる胃酸分泌亢進に対するOmeprazole注射剤の抑制効果の検討. 薬理と治療 23 (supp18):175-185, 1995

• 8) Yamamoto O, Okada Y, Okabe S:Effects of a proton pump inhibitor, omeprazole, on gastric secretion and gastric and duodenal ulcers or erosions in rats. Dig Dis Sci 29:394-401 1984
  pubmed

• 9) Wallmark B, Larsson H, Humble L:The relationship between gastric acid secretion and gastric H+,K+-ATPase activity. J Biol Chem 260:13681-13684, 1985
  pubmed

• 10) Larsson H, Carlsson E, Junggren U et al:Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology 85:900-907, 1983
  pubmed

• 11) 芳賀慶一郎, 浅野潔, 大菅邦男ほか:H+, K+-ATPase阻害薬, Omeprazoleの胃酸分泌および胃・十二指腸損傷に及ぼす影響-H2-receptor拮抗薬, Famotidineとの比較-. 日本薬理学雑誌 92:39-47 1988

• 12) 波江野力, 高橋雅俊, 西田靖仙ほか:急性出血性潰瘍に対する3剤併用療法 (Famotidine, omeprazole and ecabet sodium) の著効例. 薬理と治療 27:103-107 1999

• 13) 岸野真衣子, 光永篤, 中村真一ほか:心血管術後に発症した球後部潰瘍4症例の検討. Prog Dig Endsc 53:170-171, 1998

• 14) 中島光好, 森治樹, 斉藤良太郎ほか:特集/Omeprazole注射剤の臨床研究. 薬理と治療 23 (suppl 8):205-207, 1995

• 15) 三好秋馬, 青木照明, 松尾裕ほか:上部消化管出血に対するOmeprazole注射剤の臨床的研究-Pilot study-. 薬理と治療 23 (suppl 8):49-59, 1995

• 16) 森瀬公友, 鈴木孝, 岡勇二ほか:上部消化管出血に対するOmeprazole注射剤の止血効果およびOmeprazole経口剤の止血維持効果の検討. 薬理と治療 23 (suppl 8):101-112, 1995

• 17) 牧山和也, 原耕平, 今村和之ほか:上部消化管出血に対するOmeprazoleの臨床評価-Omeprazole注射剤による止血効果およびOmeprazole錠剤による止血維持効果の検討-. 薬理と治療 23 (suppl 8):113-125, 1995

• 18) 山西徹治, 中島彰一, 黒田留未ほか:上部消化管出血に対するOmeprazole療法止血効果ならびに止血維持効果の検討-. 薬理と治療 23 (suppl 8):127-137, 1995

• 19) Poynard T, Lemaire M, Agostini H:Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroentrol Hepatol 7:661-665, 1995
  pubmed

• 20) Lanza F, Goff J, Scowcroft C et al:Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol 89:1191-1200, 1994
  pubmed

• 21) Erstad BL:Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother 35:730-740, 2001
  pubmed

• 22) Rehner M, Rohner HG, Schepp W:Comparison of pantoprazole versus omeprazole in the treatment of acute duodcnal ulceration-a multicentre study. Aliment Pharmacol Ther 9:411-416, 1995
  pubmed

Part4 New Device-I GERD治療における最新の話題

P.151 掲載の参考文献

• 1) 本郷道夫, 唐橋一人:GERDの疫学的変遷と今後の予測. 消化器内視鏡 12:1494-1501, 2001

• 2) 本郷道夫:逆流性食道炎の病態生理. 東北医学雑誌 109:201-204, 1997

• 3) Lundell LR, Dent J, Bennett JR et al:Endoscopic assessment of oesophagitis:clinical and functional correlates and further validation of the Los Angeles classification. Gut 45:172-180, 1999

• 4) Dodds WJ, Dent J, Hogan J et al:Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 307:1547-1552, 1982

• 5) Holloway RH, Hongo M, Berger K et al:Gastric distention:Amechanism for postprandial gastroesophageal reflux. Gastroenterology 89:779-784, 1985

• 6) Boulant J, Fioramonti J, Dapoigny M et al:Cholecystokinin and nitric oxide in transient lower esophageal sphincter relaxation to gastric distention in dogs. Gastroenterology 107:1059-1066, 1994
  pubmed

• 7) Sloan S, Kahliras PJ:Impairment of esophageal emptying with hiatal hernia. Gastroenterology 100:596-605, 1991

• 8) Kahrilas PJ, Shi G, Manka M et al:Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 118:688-695, 2000
  pubmed

• 9) 本郷道夫, 上野正道:逆流性食道炎の診断と治療. Pharma Medica 411:103-109, 1993

• 10) 本郷道夫, 上野正道:逆流性食道炎. 実験治療 635:88-91, 1994

• 11) Ueno M, Hongo M:Empirical pharmacotherapy of reflux sophagitis:comparison between H2-RA for mild and PPI for severe esophagitis (abstr). Gastroenterology 114:A314, 1998

• 12) 大原秀一, 本郷道夫, 浅木茂:24時間pHモニターによるファモチジンおよびオメプラゾールの胃内pHに対する影響. 日本消化器病学会雑誌 85:1353-1359, 1988

• 13) Dent J, watts s, Riley s et al:omeprazole (OME) improves quality of life (QOL) in patients with gastroesophageal reflux disease (GERD) (abstr). Gastroenterology 110:A94, 1996

• 14) 関口利和, 遠藤光夫, 本郷道夫ほか:H?受容体拮抗剤抵抗性の逆流性食道炎に対するomeprazoleの臨床評価 (第2報). 臨床医薬 16:1387-1404, 2000
  Medical*Online

• 15) 遠藤光夫, 関口利和, 中村孝司ほか:H?受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749の臨床的有用性の検討. 臨床成人病 29 (別冊):959-976, 1999

• 16) Dimenas E:Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 199:18-21, 1993
  pubmed

• 17) Havelund T, Lind T, Wiklund I et al:Quality of life in patients with heartburn but without esophagitis:effects of treatment with omeprazole. Am J Gastroenterol 94:1782-1789, 1999
  pubmed

• 18) Robinson M:Review article:current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 13 (suppl 5):5-10, 1999

• 19) Sagar M, Seensalu R, Tybring G et al:CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicocacter pylori infection. Scand J Gastroenterol 33:1034-1038, 1998
  pubmed

• 20) Peghini PL, Katz PO, Bracy NA et al:Nocturnalrecovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767, 1998
  pubmed

• 21) Peghini PL, Katz PO, Castell DO:Ranitidine controls nocturnal gastric acid breakthrough on omeprazole:a controlled study in normal subjects. Gastroenterology 115:1335-1339, 1998
  pubmed

P.157 掲載の参考文献

• 1) Reynolds JC:Individualized acute treatment strategies for gastroesophageal reflux disease. Scand J Gastroenterol Suppl 213:17-24, 1995
  pubmed

• 2) 黒澤進, 中村孝司:GERDの治療は(1)Step-down. 臨床消化器内科 14:1577-1582, 1999

• 3) 関口利和:GERDの治療は(2)Step-up. 臨床消化器内科 14:1583-1587, 1999

• 4) Weinstein MC, Fineberg HV:Clinical decision analysis. Saunders, Philadelphia, 1980, pp1-11

• 5) Beck JR, Pauker SG:The Markov process in medical prognosis. Med Decis Making 3:419-458, 1983
  pubmed

• 6) Soga T, Matsuura M, Kodama Y et al:Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?J Gastroenterol 34:435-440, 1999
  pubmed

• 7) 吉田智治, 沖田極, 原田稔也ほか:逆流性食道炎に対するオメプラール錠の有用性の検討. 新薬と臨床 48:1431-1440, 1999

• 8) 川野淳:逆流性食道炎に対するPPIとH2RAの無作為比較試験. Ther Res 21:1330-1332, 2000

• 9) 羽生泰樹, 清田啓介, 浅田全範ほか:軽症逆流性食道炎治療におけるオメプラゾールとファモチジンの無作為比較対照試験. 新薬と臨床 49:1072-1078, 2000
  Medical*Online

• 10) 関口利和, 西岡利夫, 草野元康ほか:逆流性食道炎に対するOmeprazoleの臨床評価. 薬理と治療 16 (suppl 3):745-756, 1988

• 11) 岸清一郎, 辻泰弘, 伊東進ほか:逆流性食道炎に対するOmeprazoleの臨床的有用性の検討. 薬理と治療 16 (suppl 3):757-765, 1988

• 12) Sandmark S, Carlsson R, Fausa O et al:Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 23:625-632, 1988
  pubmed

• 13) Hetzel DJ, Dent J, Reed WD et al:Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903-912, 1988

• 14) Bate CM, Booth SN, Crowe JP et al:omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitits. Gut 36:492-498, 1995
  pubmed

• 15) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するOmeprazoleの臨床評価 (第2報) -再発予防効果と安全性の検討-. 臨床医薬 16:1387-1404, 2000

• 16) Armstrong D, Bennett JR, Blum AL et al:The endoscopic assessment of oesophagitis:progress report on observer agreement. Gastroenterology 111:85-92, 1996
  pubmed

• 17) 藤本一眞, 岡本多代, 岩切龍一:疫学からみた胃・食道逆流症. 日本内科学会雑誌 89:9-13, 2000

• 18) 本郷道夫, 菅原隆:逆食症の概念と臨床. 臨床消化器内科 10:1531-1538, 1996

• 19) DeVault KR, Castell DO:Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 94:1434-1442, 1999
  pubmed

• 20) 羽生泰樹:日本におけるGERD薬剤治療の費用効果分析-プロトンポンプ阻害剤(PPI)とH2受容体拮抗剤 (H2RA) の比較評価-. Ther Res 21:1400-1404, 2000

• 21) 羽生泰樹, 大安一也, 若松隆宏ほか:逆流性食道炎治療におけるコストベネフィット. 日本臨床 58:1881-1885, 2000
  Medical*Online

• 22) 羽生泰樹:日本における逆流性食道炎治療の費用効果分析:(I) PPI first strategyとstep-up strategy, (II) 維持療法におけるPPIとH2RAの比較評価. Ther Res 22:1067-1071, 2001

P.162 掲載の参考文献

• 1) 原澤茂:GERDの最近の考えかた. Helicobacter Research 5:337-340, 2001
  Medical*Online

• 2) 高安博之, 原澤茂, 三輪剛ほか:Non-ulcer dyspepsia 患者における胃生理機能およびHelicobacter pyloriに関する検討. 日本消化器病学会雑誌 90:743-754, 1993
  Medical*Online

• 3) 原澤茂:胃食道逆流症の内科的治療. 外科治療 85:388-393, 2001
  Medical*Online

• 4) 井本一郎:ヘリコバクター・ピロリ感染の診断及び治療の保険適応について. 日本ヘリコバクター学会誌 3:1-3, 2001

• 5) DeVault KR, Castell DO:Guidelines for the diagnois and treatmeut of gastroesophageal reflux disease. Arch Intern Med 155:2165-2173, 1995

• 6) 原澤茂:プロトンポンプ阻害薬の安全性. プロトンポンプインヒビター, 竹本忠良, 中澤三郎監修, メジカルレビュー社, 1997, pp147-156

• 7) collen MJ, strong RM:comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion. Dig Dis Sci 37:897-903, 1992
  pubmed

• 8) Paull A, Trier Js, Dalton MD et al:The histologic spectrum of Barrett's esophagus. N Engl J Med 295:476-480, 1976
  pubmed

• 9) 中島滋美, 服部隆則, 馬場忠雄:Helicobacter pyori除菌後の逆流性食道炎の発生機序と食道腺癌のリスク. 日本ヘリコバクター学会誌 3 (suppl 2):4-11, 2001

P.168 掲載の参考文献

• 1) Dent J, Jones R, Kahrilas P et al:Management of gastro-oesophageal reflux disease in general practice. BMJ 322:344-347, 2001

• 2) DeVault KR, Castell DO:Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 4:1434-1442, 1999

• 3) Dent J, Brun J, Fendrick AM et al:An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 44:S1-S16, 1999

• 4) Fendrick AM:Management of patients with symptomatic gastroesophageal reflux disease:a primary care perspective. Am J Gastroenterol 96:S29-S33, 2001
  pubmed

• 5) Fennerty MB, Castell D, Fendrick AM et al:The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment, Suggested disease management guidelines. Arch Intern Med 156:477-484, 1996

• 6) 本郷道夫:GERDガイドライン. Ther Res 20:1659-1668, 1999
  Medical*Online

• 7) Chiba N, De Gara CJ, Wilkinson JM et al:Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease:a meta-analysis. Gastroenterology 112:1798-810, 1997
  pubmed

• 8) Bell NJ, Hunt RH:Role of gastric acid suppression in the treatment of gastrooesophageal reflux disease. Gut 33:118-124, 1992
  pubmed

• 9) van Pinxteren B, Numans ME, Bonis PA et al:Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Datahase Syst Rev (2):CD002095, 2000
  pubmed

• 10) Caro JJ, Salas M, Ward A:Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo:evidence from randomized clinical trials. Clin Ther 23:998-1017, 2001
  pubmed

• 11) Peghini PL, Katz PO, Castell DO:Ranitidine controls nocturnal gastric acid breakthrough on omeprazole:a controlled study in normal subjects. Gastroenterology 115:1335-1339, 1998
  pubmed

• 12) Fackler WK, Ours TM, Vaezi MF:Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122:625-632, 2002

• 13) Kitchin H, Castell DO:Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 151:448-454, 1991

• 14) 羽生泰樹, 大安一也, 若松隆宏ほか:逆流性食道炎治療におけるコストベネフィット. 日本臨床 58:1881-1885, 2000
  Medical*Online

• 15) Carlsson R, Galrniche JP et al:Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs:a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 11:473-482, 1997

• 16) Talley NJ, Lauritsen K, Tunturi-Hihnala H:Esomeprazole 20 mg maintains symptom controlin endoscopy-negative gastro-oesophageal reflux disease:a controlled trial of`on-demand' therapy for 6 months. Aliment Pharmacol Ther 15:347-354, 2001

• 17) Lind T, Havelund T, Lundell L et al:On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther 13:907-914, 1999

P.172 掲載の参考文献

• 1) Heading RC:Epidemiology of oesophageal reflux disease. Scand J Gastroenterol Suppl 168:33-37, 1989
  pubmed

• 2) Furukawa N, Iwakiri R, Koyama T et al:Proportion of reflux esophagitis in Japanese adults:prospective evaluation by endoscopy. J Gastroenterol 34:441-444, 1999
  pubmed

• 3) Kang JY, Ho KY:Different prevalences of reflux esophagitis and hiatus hernia among dyspeptic patients in England and Singapore. Eur J Gastroenterol Hepatol 11:845-850, 1999
  pubmed

• 4) 関口利和, 堀越勤:胃食道逆流症の病態と治療. 日本医事新報 3830:1-5, 1997

• 5) 桜井幸広:逆流性食道炎の時代的変遷. 胃と腸 34:963-969, 1999

• 6) 幕内博康:滑脱型食道裂孔ヘルニアの臨床的研究-診断基準と程度分類を中心に-. 日本消化器病学会雑誌 79:1557-1567, 1982

• 7) 中村孝司, 塩島純子, 黒澤進ほか:GERDと自覚症状. GERDの診断と治療-GERDの臨床と今日的意義-, メディカルビュー社, 東京, 1999, pp13-23

• 8) Bell NJ, Burget D, Howden CW V et al:Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51 (suppl 1):59-67, 1992

• 9) An evidenced-based appraisal of reflux disease management-the Genval Workshop report. Gut 44 (suppl):S1-S16, 1999

• 10) DeVault KR, Castell DO:Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 94:1434-1442, 1999
  pubmed

• 11) Bate cM, Booth SN, Crowe JP et al:Omeprazol 10mg or 20mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 36:492-498, 1995

• 12) Gough AL, Long RG, Cooper BT et al:Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 10:529-539, 1996
  pubmed

• 13) 関口利和, 遠藤光夫, 本郷道夫ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するOmeprazoleの臨床評価 (第2報) -再発予防効果と安全性の検討-. 臨床医薬 16:1387-1404, 2000

• 14) 遠藤光夫, 関口利和, 中村孝司ほか:H2受容体拮抗剤抵抗性の逆流性食道炎に対するAG-1749の臨床的有用性の検討-第二報維持効果の検討-. 臨床成人病 29:959-977, 1999

• 15) 黒澤進, 西川滋人, 金子操ほか:逆流性食道炎の内科的治療法. 現代医療 27:1424-1431, 1995

• 16) Havu N:Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35 (suppl 1):42-55, 1986

• 17) 佐々木啓, 宮蔦宏彰:胃酸分泌抑制剤とECL細胞カルチノイド. 薬理と治療 20:4315-4323, 1992

• 18) McTavish D, Buckley MM, Heel RC:Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 42:138-170, 1991
  pubmed

• 19) Hixson LJ, Kelley CL, Jones WN et al:Current trends in the pharmacotherapy for gastroesophageal reflux disease. Arch Intern Med 152:717-723 1992
  pubmed

• 20) McCloy RF:Implications of review of long-term safety of omeprazole and management strategies for peptic disease. Hepato-gastroenterol 39 (suppl):90-91, 1992

• 21) 友野寛樹, 屋嘉比康治, 中村孝司ほか:単離壁細胞におけるproton pump inhibitorの酸分泌抑制効果. 日本消化器病学会雑誌 89:342, 1992

• 22) Peghini, PL Katz PO, Bnacy NA et al:Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pomp inhibitors. Am J Gastroenterol 93:763-767, 1998

• 23) Gedda K, Scolt D, Besancon M et al:The half life at the H. K-ATPase of gastric mucosa. Gastroenterology 106:A79, 1994

• 24) Huber R, Kohl B, Sachs G et al:Review article:The continuing development of proton pompinhibitors with particular reference to pantoprazole. Aliment Pharmocol Ther 9:363-378, 1995

• 25) Katz PO, Anderson C, Khoury R et al:Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pomp inhibitors. Aliment Pharmacol Ther 12:1231-1234, 1998

• 26) Kasube T, Adachi K, Kawamura A et al:Helicobacter pylori:infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049-1056, 2000

• 27) Hatlebakk JG, Katz Po, Kuo B et al:Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40mg daily. Aliment Pharmacol Ther 12:1235-1240, 1998

• 28) Peghini PL Katz PO, Castell DO et al:Ranitidine controls nocturnal gastric acid breakthrough on omeprazole:A controlled study in normal subjects. Gastroenterology 155:1335-1339, 1998

P.177 掲載の参考文献

• 1) 大原秀一, 関根仁, 飯島克則ほか:老年者逆流性食道炎における胃粘膜萎縮とHelicobacter pylori感染の検討. 日本消化器病学会雑誌 93 (4):235-239, 1996
  Medical*Online

• 2) Koike T, Ohara S, Sekine H et al:Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 94:3468-3472, 1999
  pubmed

• 3) Koike T, Ohara S, Sekine H et al:Helicohacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 3:330-334, 2001

• 4) Koike T, Ohara S, Sekine H et al:Increased gastric acid secretion after Helicohacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther 15:813-20, 2001

• 5) 小池智幸, 大原秀一, 関根仁ほか:胃食道逆流症の臨床病態-特に酸分泌能からみた逆流性食道炎の病態-. 消化器科 28:321-326, 1999

• 6) 本郷道夫, 菅原隆:逆流性食道炎の概念と臨床. 臨床消化器内科 11:1531-1538, 1996

• 7) Martinek J, Kuzela L, spicak A et al:Review article:the clinical influence of Helicobhacter pylori in effective acid suppression-implications for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:979-990, 2000

• 8) Verdu EF, Armstrong D, Fraser R et al:Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 36:539-543, 1995
  pubmed

• 9) Gillen D, Wirz AA, Neithercut WD et al:Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 44:468-475, 1999
  pubmed

• 10) Verdu EF, Armstrong D, Idstrom JP et al:Effect of curing Helicohacter pylori infection on intragastric pH during treatment with omeprazole. Gut 37:743-748, 1995

• 11) Martinek J, Blum AL, stolte M et al:Effect of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 13:27-34, 1999
  pubmed

• 12) Verdu EF, Armstrong D, Idstrom Jp et al:Intragastric pH during treatment with omeprazole:role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 31:1151-1156, 1996

• 13) Labenz J, Tillenburg B, Peitz u et al:Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 110:725-732, 1996

• 14) Labenz J, Tillenburg B, Peitz u et al:Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 92:576-581, 1997
  pubmed

• 15) van Herwaarden MA, Samsom M, van Nispen CH et al:The effect of Helicobacter pylori eradication on intragastric pH during dosing withlansoprazole or ranitidine. Aliment Pharmacol Ther 13:731-740, 1999
  pubmed

• 16) Koop H, Kuly S, Flug M et al:Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Am J Gastroenterol Hepatol 8:915-918, 1996

• 17) Peghini PL, Katz PO, Bracy NA et al:Nocturnalrecovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767, 1998
  pubmed

• 18) Katsube T, Adachi K, Kawamura A et al:Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049-1056, 2000
  pubmed

• 19) Schenk BE, Kuipers EJ, Klinkenberg-Knol EC etal:Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal refluxdisease. Am J Gastroenterol 94:884-887, 1999

• 20) Talley NJ, Meineche-Schmidt v, Pare P et al:Efficacy of omeprazole in functional dyspepsia:double-blind, randomized, placebo-controlled trials (the Bond and Opera studies) . Aliment Pharmacol Ther 12:1055-1065, 1998
  pubmed

• 21) Holtmann G, Cain C, Malfertheiner P et al:Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117:11-16, 1999
  pubmed

• 22) Hatlebakk JG, Berstad A:Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Aliment Pharmacol Ther 11:1093-1099, 1997
  pubmed

• 23) Carlsson R:Gastro-oesophageal Reflux Disease. A Study of Pathophysiology, Clinical Diagnosis and Management (Thesis). Gothenburg University, 1998

• 24) Lundell L:Gastro-oesophageal reflux disease and Helicocacter pylori or gastro-oesophageal reflux disease from Helicobacter pylori? Gastroenterol Hepatol 13 (suppl 1) S23-S27, 2001

• 25) Moayyedi P, Bardhan C, Young L et al:Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121:1120-1126, 2001

Part5 New Device-II Helicobacter pylori除菌療法への適用

P.183 掲載の参考文献

• 1) Kasai K, Kobayashi R:The stomach spirochete occuring in mammals. J Parasitiol 6:1-10, 1919

• 2) Tytgat GNJ, Axon ATR, Dixon MF et al:Helicobacter pylori:causal agent in peptic ulcer disease? Working party reports of the world congresses of gastroenterology, Blackwell Scientific Pub, Melbourne, 1990, pp36-45

• 3) Warren JR, Marshall B:unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i:1273-1275, 1983
  pubmed

• 4) Van der Hulst RW, Rauws EA, Koycu B et al:Prevention of ulcer recurrence after eradication of Helicobacter pylori:a prospective long-term follow-up study. Gastroenterology 113:1082-1086, 1997
  pubmed

• 5) Uemura N, Okamoto S, Yamamoto S et al:Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784-789, 2001
  pubmed

• 6) Bayerdorffer E, Neubauer A, Rudolph B et al:Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345:1591-1594, 1995

• 7) Hanlma K, Mihara M, Okamoto E et al:Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Thber 13:155-162, 1999

• 8) Lagergren J, Bergstrom R, Lindgren A et al:Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825-831, 1999
  pubmed

• 9) El-Omar EM, Carrington M, Chow WH et al:Interleukin-1 polymorphism associated with increased risk of gastric cancer. Nature 404:398-402, 2000
  pubmed

• 10) Fujioka T, Fuliyama K, Hiramatsu K et al:In vitro activity of novel proton pump inhibitors against Helicobacter pylori. In:Recent Advances in Chemotherapy, ed by Einhorn J et al, ASM, Washington DC, 1995, pp 612-613

• 11) Miwa H, Ohkura R, Murai T et al:Impact ofrabeprazole, a new proton pump inhibitor, intriple therapy for Helicobacter pylori infection comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 13:741-746, 1999
  pubmed

• 12) Sachs G, shin JM, Munson K:Review article:the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther 14:1383-1401, 2000
  pubmed

• 13) Gustavson LE, Kaiser JF, Edomonds AL et al:Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicroh Agents Chemother 39:2078-2083, 1995

• 14) Lind T, Megraud F, unge P et al:The MACH2 study:role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253, 1999
  pubmed

• 15) Asaka M, Sugiyama T, Kato M et al:A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261, 2001

• 16) 桑山肇, 吉田俊一, 中村武史ほか:オメプラゾール, アモキシシリンおよびクラリスロマイシンの3剤併用によるHelicobacter pyroli:除菌療法の第III相二重盲検比較試験. 第7回日本ヘリコバクター学会抄録集, p155, 2001

• 17) 菅野健太郎:特集「Helicohacter」pylori除菌失敗例の取り扱い (序) 」Helicobacter Research 5:451-452, 2001

P.191 掲載の参考文献

• 1) 厚生省保険局医療課長通知保険発第180号:ヘリコバクター・ピロリ感染の診断及び治療に関する取扱いについて, 平成12年10月31日

• 2) 大原秀一, 加藤元嗣, 浅香正博ほか:13C-UBT を用いたC13-尿素呼気試験のFDAのH. pylori感染判定基準を用いた検討. 新薬と臨床 49:948-965, 2000

• 3) 白井孝之, 三輪剛:ウレアーゼ活性を用いた検出法 (biopsy urease test) . Helicobacter pyloriの最新知見, 日本消化器病学会編, 中山書店, 東京, pp176-180, 1995

• 4) 神谷茂:培養検査はどこまで保険でカバーしてもらえるのか?Helicobacter Research 5:216-219, 2001
  Medical*Online

• 5) Asaka M, Sugiyama T, Kato M et al:A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261, 2001

• 6) Ikezawa K, Yoshida T, Shimakura S et al:Cost-effectiveness of the PPI triple therarpy with minocycline and metronidazole in Helicobacter pylori eradication. 第6回日本ヘリコバクター学会抄録集, p161, 2000

• 7) 榊信廣:消化性潰瘍の内視鏡的時相分類と除菌開始時期. Helicobacter Research 5:192-194, 2001
  Medical*Online

• 8) Gene E, Calvet X, Azagra R:Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers-a cost-effectiveness analysis. Aliment Pharmacol Ther 14:433-442, 2000
  pubmed

• 9) Griffiths RI, Rabeneck L, Guzman G et al:Costs of Managing Helicobacter pylori-infected ulcer patients after initial therapy. Helicobacter 6:66-76, 2001
  pubmed

• 10) 飯野四郎, 安田清美, 小林慎ほか:C型慢性肝炎に対するIFN療法の費用効果分析-活動投与と非活動性投与の比較-. 日本馨事新報 3870:10-15 (平成10年6月27日)

• 11) 菅野健太郎:プロトンポンプ阻害薬の医療経済効果. nano GIGA 3:105-112, 1994

• 12) 大原秀一, 下瀬川徹:Helicobacter pylori除菌治療の医療経済効果. Helicobacter Research 4:238-242, 2000
  Medical*Online

• 13) 大原秀一, 下瀬川徹:胃潰瘍におけるH. pylori 除菌と維持療法の医療経済比較. 消化器科 32:305-310, 2001

• 14) 池田俊也, 圭室俊雄, 浅香正博:Helicobacter pylori除菌3剤併用療法の薬剤経済学的分析. Helicobacter Research 4:563-567, 2000
  Medical*Online

• 15) 野末睦, 丸山常彦, 今村史人ほか:直接および間接人件費計算法による胃切除術症例の原価計算. 癌と化学療法 27:1369-1374, 2000
  Medical*Online

• 16) Uemura N, Okamoto S, Yamamoto S et al:Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784-789, 2001
  pubmed

P.196 掲載の参考文献

• 1) NIH consensus Conference:Heltcobacter pylori in peptic ulcer disease. JAMA 272:65-69, 1994

• 2) International agency for research on cancer, World Health Organization:Schistosomes, liver Hukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risk Hum 61:177-241, 1994

• 3) The European Helicobacter pylori Study Group:Current European concepts in the managernent of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41:8-13, 1997

• 4) American Digestive Health Foundation:The report of the digestive health initiative international update conference on Helicobacter pylori. Washington DC, 1997

• 5) Lam SK, Talley NJ:Report of the 1997 Asian Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13:1-12, 1998
  pubmed

• 6) Rubin GP, Meineche-Schmidt V, Roberts AP et al:The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care. Family Practice 17 (suppl):S21-S26, 2000

• 7) Malfertheiner P, Megraud F, O:Morain C et al:Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180, 2002
  pubmed

• 8) Sherman P, Hassall E, Hunt RH et al:Canadian Helicobacter Study Group Consensus Conference on the Approach to Helicobacter pylori Infection in Children and Adolescents. Can J Gastroenterol 13:553-559, 1999

• 9) Drumm B, Koletzko S, Oderda G:Helicobacter pylori infection in children:a consensus statement. J Pediatr Gastroenterol Nutr 30:207-213, 2000
  pubmed

• 10) Helicobacter pylori治験検討委員会:Helicocacter pylori治験ガイドライン, 1995

• 11) Helicobacter pylori治験検討委員会:Helicobacter pylori治験ガイドライン. 日本消化器病学会雑誌 96:199-207, 1999
  Medical*Online

• 12) 日本ヘリコバクター学会ガイドライン作成委員会:H. Rvlori感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 2 (suppl):1-12, 2000

• 13) Asaka M, Satoh K, Sugano K et al:Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 6:177-186, 2001
  pubmed

• 14) 加藤晴一, 小林昭夫, 杉山敏郎ほか:小児の Helicohacter pylori除菌療法に関するガイドライン (案) の提唱. 日本小児栄養消化器病学会誌 11:173-176, 1997

• 15) Asaka M, Sugiyama T, Kato M et al:A multicenter, double-blind study on triple therapy with lansoprazole, amoxicilin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6:254-261, 2001

• 16) Kato M, Yamaoka Y, Kim JJ et al:Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 44:2214-2216, 2000
  pubmed

P.205 掲載の参考文献

• 1) 鎌田智有, 春間賢, 吉原正治ほか:除菌後再発潰瘍の分析. 日本臨床 (増刊号) 2:501-505, 2002

• 2) Wilhelmsen I:Quality of life and Helicobacter pylori eradication. Scand J Gastroenterol 31 (suppl 221):18-20, 1996

• 3) Grawley J, Frank L, Joshua-Gotlib s et al:Measurng change in qualiy of life in response to Helicobacter pylori eradication in peptic ulcer disease. The QOLRAD. Dig Dis Sci 46:571-580, 2001

• 4) 福田能啓, 田中淳二, 富田寿彦ほか:Helicobacter pylori除菌後のQOL. Heltcobacter Research 5:48-53, 2001

• 5) 遠藤由香, 本郷道夫:機能性ディスペプシアとQOL. 臨床消化器内科 15:19-24, 2000

• 6) McColl K, Murray L, El-Omar E et al:Symptomatic benefit from eradicating Heltcobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 339:1869-1874, 1998
  pubmed

• 7) Moayyedi P, Feltbower R, Brown J et al:Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community:a randomised controlled trial. Lancet 355:1665-1669, 2000
  pubmed

• 8) 佐竹学, 本郷道夫:除菌後食道炎の発生に関する問題点. 内科 89:471-474, 2002

• 9) 鎌田智有, 春間賢, 吉原正治ほか:Helicobacter pylori除菌後の背景胃粘膜性状と潰瘍の再発. 胃と腸 35:637-646, 2000

• 10) 藤原靖弘, 樋口和秀, 斯波将次ほか:除菌後の肥満出現の頻度と対処法. Helicobacter Research 5:283-285, 2001
  Medical*Online

P.210 掲載の参考文献

• 1) Marshall BJ, Goodwin CS, Carren JR et al:Prospective double-blind trial of duodcnal ulcer relapse after eradication of Campylobacter pylori. Lancet 11:1437-1442, 1988

• 2) 村上和成:Helicobacter pylori除菌後の潰瘍再発の実際. Helicobacter Research 5:8-11, 2001
  Medical*Online

• 3) Van der Hulst RW, Rauws EA, Koycu B et al:Prevention of ulcer recurrence after eradication of Helicobacter pylori:A prospective long-term follow up study. Gastroenterology 113:1082-1086, 1997
  pubmed

• 4) Marshall BJ:Helicobacter pylori Am J Gastroenterol 89(suppl):S116-S128, 1994

• 5) 西川恵子, 杉山敏郎, 石塚淳ほか:Helicobacter pylori除菌後に再発する消化性潰瘍の現状とその対策. Helicobacter Research 5:37-41, 2001

• 6) 榊信廣:Helicobacter pylori除菌療法後の維持療法は必要か? Helicobacter Research 4:223-236, 2000

• 7) 関根仁, 浅木茂:ヘリコバクター・ピロリの除菌治療の成績と除菌後の諸問題. Medical Practice 12:2049-2053, 2001
  Medical*Online

• 8) 川上順, 佐藤貴一, 木平健ほか:Helicobacter pylori除菌後の消化性潰瘍再発にNSAIDsが及ぼす影響. Helicobacter Research 4:326-331, 2000

• 9) McColl KE, el-Nujumi AM, Chittajallus RS et al:A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 34:762-768, 1993

• 10) Borody TJ, George LL, Brandl S et al:Helicohacter pylori negative duodenal ulcer. Am J Gastroenterol 86:1154-1157, 1991

• 11) 田中達朗, 星原芳雄, 山本敬ほか:消化性潰瘍のHelicobacter pylori:除菌後の再発. 胃と腸 35:623-630, 2000

• 12) 内藤裕二, 吉川敏一:Helicobacter pylori除菌後のNSAIDs病変とその対策. Helicobacter Research 5:2-46, 2001

• 13) 菅野健太郎:ヘリコバクター・ピロリ除菌時代の消化性潰瘍の治療戦略. Medical Practice 18:1954-1960, 2001
  Medical*Online

• 14) 佐々木誠人, 城卓志, 伊藤誠ほか:胃潰瘍と十二指腸潰瘍における再発因子としてのHelicobacter pyloriの重要度. 胃と腸 35:647-654, 2000

P.215 掲載の参考文献

• 1) Huang JQ, Hunt RH:Treatment after failure:the problem of"non-responders". Gut 45 (suppl 1):140-144, 1999

• 2) Graham D, Lew GM, Malaty HM et al:Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493-496, 1992
  pubmed

• 3) Wermeille J, Dederding JP, Cunningham M et al:Failure of Helicobacter pylori eradication in an ambulatory population:is poor compliance the main cause? Digestion 59 (suppl 3):437, 1998

• 4) Kearney DJ:Retreeatment of Helicobacter pylori infection after initial treatment failure. Am J Gastroenterol 96:1335-1339, 2001
  pubmed

• 5) Nagahara A, Miwa H, Ogawa K et al:Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 5:88-93, 2000
  pubmed

• 6) Fennerty MB, Lieberman DA, Vakil N et al:Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Mea 159:1562-1566, 1999

• 7) 浅香正博, 菅野健太郎, 杉山敏郎ほか:Helicobacter pylori感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 (suppl):2-12, 2000
  Medical*Online

• 8) Miwa H, Misawa H, Yamada T et al:Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H .pylori infection:a multiple logistic regression analysis. Dig Dis Sci 46:2445-2450, 2001
  pubmed

• 9) 村上和成, 藤岡利生, 那須勝:ヘリコバクターピロリ除菌治療に対する薬剤耐性の影響. 日本化学療法学会雑誌 46 (suppl B):82, 1998

• 10) Miwa H, Murai T, Sato K et al:Comparison of the efficacy of 400mg and 800mg of clarithromycin use with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. J Gastroenterol 35:536-539, 2000

• 11) Graham DY, Qureshi WA:Antibiotic-resistant H. pylori infection and its treatment. Curr Pharm Des 6:1537-1544, 2000
  pubmed

• 12) 0sato MS, Reddy R, Reddy SG et al:Reliable determination of metronidazole and clarithromycin susceptibility;comparison of methods and assessment of internal variability using simultaneously obtained antral and corpus biopsies. Gastroenterology 118:A676, 2000

• 13) Megraud F, Lehn N, Lind T et al:Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial;the MACH 2 study. Antimicrob Agents Chemother 43:2747-2752, 1999

• 14) Gisbert Jp, Boixeda D, Bermejo F et al:Retreatment after H. pylori eradication failure:which therapy is better? Digestion 59 (suppl 3):410, 1998

• 15) Houben MHMG, van de beek D, van't Hoff BWN et al:PPI-triple therapy failure in Helicobacter pylori (Hp) infection:Re-treatment with PPI-triple therapy of quadruple therapy? Digestion 59 (suppl 3):413, 1998

• 16) Pieramico O, Zanetti MV:Treatment with quadruple therapy after triple therapy failure inpatients infected with H. pylori resistant strains (abstr). Gastroenterology 116:A282, 1999

• 17) Gisbert Jp, Gisbert JL, Marcos s et al:seven-day`rescue' therapy after Helicobacter pylori treatment failure:omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 13:1311-1316, 1999
  pubmed

• 18) Houben MH, Van Der Beek D, Hensen EF et al:A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rate. Aliment Pharmacol Ther 13:1047-1055, 1999

• 19) Van der Wouden EJ, Thijs Jo, zwet AA et al:The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapyregimens for Helicobacter pylori infection. Aliment Phamaacol Ther 13:297-302, 1991

• 20) Williamson R, Pipkin GA, wood JR:New optionsin Helicobacter pylori eradication;efficacy, resistance and synergy. Scand J Gastroenterol Suppl 225:36-40, 1998

• 21) Van der wouden EJ, Thijs Jo, zwet AA et al:One-week triple therapy with ranitidine bismuthcitrate, clarithromycin and metronidazole versustwo-week dual therapy with ranitidine bismuthcitrate and clarithromycin for Helicobacter pylori infection;Arandomized, clinical trial. Am J Gastroenterol 93:1228-1231, 1998

• 22) 河合隆, 石垣雅子, 笹津備規ほか:初回除菌方法別の再除菌療法の検討. 第5回日本ヘリコバクター学会抄録集, 新潟, 1999, p60

• 23) 村上和成, 藤岡利生, 久保田利博ほか:抗菌剤の併用効果と薬剤耐性を考慮したH, pylori除菌のsecond-line therapy. 第6回日本ヘリコバクター学会抄録集, 東京, 2000, p73

• 24) 車田知之, 甲田勝昭, 白井孝之ほか:除菌失敗例における3種類の2nd line regimenの治療効果. 第7回日本ヘリコバクター学会抄録, 2001, p70

• 25) 村上和成, 佐藤竜吾, 藤岡利生:H. pylori除菌療法の初回除菌治療, 再除菌治療における薬剤耐性の及ぼす影響について. 第43回日本消化器病学会大会抄録, 京都, 2001 (CD-ROM版)

• 26) Nagahara A, Miwa H, Ohkura R et al:Strategy forre-treatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 16:613-618, 2001

• 27) Lee JM, Breslin NP, Hyde DK et al:Treatmentoptions for Helicobacter pylori infection when proton pump inhibitor-based triple therapy failsin clinical Practice:Aliment Pharmacol Ther 13:489-496, 1999

• 28) Perri F, Festa V, Clemente R et al:Randomizedstudy of two"rescue"therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 96:58-62, 2001

P.220 掲載の参考文献

• 1) Miwa H, Yamada T, Sato K et al:Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection.comparison of 20 and 40 mg rabeprazole with 60mg lansoprazole.Dig Dis Sci 45:77-82,2000

• 2) Kiyota K,Habu Y, Sugano Y et al:Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarythromycin in peptic ulcer patients with Helicobacter Pylori infection. Results of a randomized controlled study. J Gastroenterol 34(suppl 11):76-79,1999

• 3) Hoshiya S, Watanabe K, Tokunaga K et al:Relationship between eradication therapy and clarythromycin resistant Helicobacter Pylori in Japan.J Gastroenterol 35:10-14,2000

• 4) Tanimura H, Kawano S, Kubo M et al:Does Helicobacter Pylori eradication depend on the period of amoxicillin treatment? A retrospective study.J Gastroenterol 33:23-26,1998
  pubmed

P.223 掲載の参考文献

• 1) Moayyedi P, Feltbower R, Brown J et al:Effect of population screening and treatment for Heltcobacter Pylori on dyspepsia and quality of life in the community:a randomised controlled trial. Leeds HELP Study Group. Lancet 255:1665-1669,2000

• 2) Wilhelmsen I, Berstad A:Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter Pylori. Scan J Gastroenterol 29:874-879,1994

• 3) 藤原靖弘, 樋口和秀:成人病発生およびQuality of life よりみた除菌療法の長期予後. 日本消化器病学会雑誌 97:A64,2000

• 4) 藤原靖弘, 樋口和秀, 内田俊之ほか:H.pylori 除菌と生活習慣病の発生. 消化器科 32 (3):299-304, 2001

• 5) 藤原靖弘, 樋口和秀, 内田俊之ほか:除菌後の肥満出現の頻度と対処法. Helicobacter Research 5 (3):283-285,2001
  Medical*Online

• 6) Fujiwara Y, Higuchi K, Arafa UA et al:Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology (in press)

• 7) 須藤弘之, 東健:Helicobacter pylori除菌治療と肥満. 日本消化器病学会雑誌 97:A456,2000

• 8) 吉田隆久, 花井洋行:H.Pylori除菌治療後の消化能, 栄養状態の変化. 日本消化器病学会雑誌 97:A64,2000

• 9) 能城充弘, 楠神和男:Helicobacter pylori除菌後の動脈硬化の risk factor の変化に関する検討. 日本消化器病学会雑誌 97:A64,2000

• 10) 菱木智, 志和忠志, 横山知子ほか:心血管系疾患の危険因子に対する Helicobacter pylori除菌治療の影響. 日本消化器病学会雑誌 98:814-821,2001
  Medical*Online

P.226 掲載の参考文献

• 1) 日本ヘリコバクター学会ガイドライン作成委員会:H.Pylori感染の診断と治療のガイドライン. 日本ヘリコバクター学会誌 2(suppl):2-12,2000
  Medical*Online

• 2) Iwahi T,Satoh H,Nakao M et al:Lansoprazole,a novel benzimidazole proton pump inhibitor,and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents chemother 35:490-496,1991
  pubmed

• 3) Nagata K, Satoh H, Iwahi T et al:Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori:unique action selective for H.Pylori cells. Antimicrob Agents Chemother 37:769-774,1993
  pubmed

• 4) Chey WD, Spybrook M, Carpenter S et al:Prolonged effect of omeprazole on the 14C-urea breath test. Am J Gastroenterol 91:89-92,1996
  pubmed

• 5) El-Nujumi A, Hilditch TE, Williams C et al:Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the 14C-urea breath test. Eur J Gastroenterol Hepatol 10:759-764,1998
  pubmed

• 6) Laine L, Estrada R, Trujillo M et al:Effect of proton pump inhibitor therpy on diagnostic testing for Helicohacter pylori. Ann Intern Med 129:547-550,1998

• 7) Hamlet A, Stage L, Lonroth H et al:A novel tablet-based 13C-urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy. Scand J Gastroenterol 34:367-374,1999
  pubmed

• 8) Savarino V, Bisso G, Pivari M et al:Effect of gastric acid suppression on 13C-urea breath test:comparison of ranitidine with omeprazole. Aliment Pharmacol Ther 14:291-297,2000
  pubmed

• 9) Culter AF, Elnaggar M, Brooks E et al:Effect of standard and high dose ranitidine on 13C-urea breath test results. Am J Gastroenterol 93:1297-1299,1998

Part6 Attention プロトンポンプ阻害薬における治療上の注意点

P.230 掲載の参考文献

• 1) Chun AH, Eason CJ, Shi HH et al:Lansoprazol:an alternative method of administration of a capsule dosage formulation. Clin Ther 17:441-447,1995
  pubmed

• 2) Furuta T, Ohashi K, Kosuge K et al:CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.Clin Pharmacol Ther 65:552-561,1999
  pubmed

• 3) Swan SK, Hoyumpa AM, Merritt GJ:Review article:the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 13 (suppl 3):11-17,1999

• 4) Eissele R, Brunner G, Simin B et al:Gastric mucosa during treatment with lansoprazole:Helicobater pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterol 112:707-717,1997

• 5) Brunner G, Arnold R, Hennig U et al:An open trial of longterm therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.Aliment Pharmacol Ther 7(suppl 1):51-55,1993

• 6) Sood A, Sharma M, Jain NP et al:Esophageal candidasis following omeprazole therapy:a report of two cases. Indian J Gastroenterol 14:71-72,1995

• 7) Fried M, Siegrist H, Frei R et al:Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 35:23-26,1994
  pubmed

• 8) Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al:Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334:1018-1022,1996
  pubmed

• 9) 上村直実, 岡本志朗:Helicobacter pylori陽性症例におけるPPI投与と炎症の進展. 臨床消化器内科 13:1399-1405,1998

P.233 掲載の参考文献

• 1) Delhotal-Landes B, Cournot A, Vemmerie N et al:The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 3:315-320,1991

• 2) 石野祐三子, 木平建,菅野健太郎:消化器治療薬を知る!プロトンポンプ阻害薬. Medicina 37:1743-1745, 2000

• 3) プロトンポンプインヒビター21世紀への展開, 竹本忠良, 中澤三郎監修, メディカルレビュー社,1998,p150

• 4) オメプラール注用20:医薬品インタビューフォーム,日本標準商品分類番号872329,2001

• 5) 古田隆久:H. pylori除菌療法と PPI-CYP2C19の遺伝子的多型との関連より-. ヘリコバクター・ピロリ・フォーラム病態と治療の最前線, 藤岡利生, 榊信廣編, 医学書院,2000,pp110-117

• 6) Humphries TJ:Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci 36:1665-1669,1991
  pubmed

• 7) 三輪清,三谷政義,塚本剛司ほか:新規プロトンポンプ阻害剤 AG-1749のラット, マウス, イヌにおける生体内動態. 薬理と治療 18:3413-3435,1990
  Medical*Online

• 8) Kokufu T, Ihara N, Sugioka N et al:Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eurl J Clin Pharmacol 48:391-395,1995

P.246 掲載の参考文献

• 1) 小林壮光,矢花剛:PPIの副作用とその発生機序.中村孝司編, H. Pylori除菌時代の消化性潰瘍の治療.日本メディカルセンター, 東京,2000,pp 205-209

• 2) 矢花剛,落合亨,小林壮光:プロトンポンプ阻害剤の使用上の注意.Medicina 130:1650-1652,1993

• 3) 山本昇:4.副作用対策. 抗悪性腫瘍ハンドブック,西條宏編,中外医学社,東京,2000,pp 28-57

• 4) 岡原聡,松永隆裕,高岡朝子ほか:PPI長期投与の問題点.臨牀消化器内科 17:209-215,2002

• 5) 東納重隆,宮原透:プロトンポンプ阻害薬の副作用とその対策.薬局 12:1857-1861,1995
  Medical*Online

• 6) Carlsson E, Larsson H, Mattsson H et al:Pharmacology and toxicology of omeprazole with special reference to the effects on the gastric mucosa. Scand J Gastroenterol 118:31-38,1986

• 7) Walsh JH:Role of gastrin as a trophic hormone. Digestion 47(suppl 1):11-16,1990

• 8) Solcia E,Bordi C,Creutzfeldt W et al:Histopathological classification of nonantral gastric endocrine growth in man. Digestion 41:185-200,1988
  pubmed

• 9) Kuipers EJ,Uyterlinde AM,Pena AS:Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy:Implications for long-term safety. Am J Gastroenterol 90:1401-1406,1995
  pubmed

• 10) Odou P, Martin P,Membre S et al:Omeprazole-induced leucopenia. A case report.J Clin Pharm Ther 24:317-321,1999
  pubmed

• 11) Marks DR,Joy JV, Bonheim NA:Hemolytic anemia associated with the use of omeprazole. Am J Gastroenterol 86:217-218,1991
  pubmed

• 12) 鈴木剛,林達之,野中泰延ほか:Lansoprazoleにより誘発された急性免疫性溶血性貧血. 臨床血液 37:1389-1394,1996

• 13) 林原歳久:抗オメプラゾール抗体による溶血性貧血および血小板減少症. 臨床血液 39:447-452,1997

• 14) Christe C, Stoller R, Vogot N:Omeprazole-induced hepatotoxicity? A case report. Pharmacoepidemiol Drug Saf 7(suppl 1):S41-S44,1998

• 15) Jochem V, Kirkpatrick R, Greenson J et al:Fulminant hepatic failure related to omeprazole. Am J Gastroenterol 87:523-525,1992
  pubmed

• 16) 石井邦英,神代龍吉,内村恭代ほか:オメプラゾールによる劇症肝炎の1剖検例.肝臓 39:877,1998

• 17) Myers RP, McLaughlin K, Hollomby DJ:Acute interstitial nephritis due to omeprazole. Am J Gastroenterol 96:3428-3431,2001
  pubmed

• 18) Ruffenach SJ, Siskind MS, Lien YH:Acute interstitial nephritis due to omeprazole. Am J Med 93:472-473,1992.
  pubmed

• 19) Landray MJ, Ringrose T, Ferner RE et al:Pyrexia, anemia and acute renal failure secondary to omeprazole. Postgrad Med J 74:416-418,1998
  pubmed

• 20) Cox NH:Acute disseminated epidermal necrosis due to omeprazole. Lancet 340:857,1992
  pubmed

• 21) 仲川義人,細貝順:プロトンポンプ阻害薬とH2 受容体拮抗薬-副作用,相互作用および使用上の注意.薬のサイエンス 3:68-74,2000

• 22) 笹井貴子,平石秀幸,生沼健司ほか:プロトンポンプ阻害薬による中毒性表皮壊死症.綜合臨牀 48:1525-1527,1999
  Medical*Online

• 23) 宮田聡子,矢口厚,橋本明彦ほか:オメプラゾールが原因と考えられたTEN型薬疹. 西日本皮膚 58:574-577,1996

• 24) 南光弘子:本邦における Toxic Epidermal Necrolysis 126例の臨床的解析. 皮膚臨床 33:1249-1263,1991

• 25) Schonhofer PS:Intravenous omeprazole and blindness.Lancet 343:665,1994

• 26) Colin-Jones D:Safety of omeprazole and lansoprazole. Lancet 343:1369,1994
  pubmed

• 27) Schonhofer PS:Safety of omeprazole and lansoprazole. Lancet 343:1369-1370,1994
  pubmed

• 28) 河野通盛,山田稔,奥村剛清ほか:プロトンポンプ阻害剤により視力障害をきたした2症例.日消誌 97:575-579,2000
  Medical*Online

• 29) 内海恵子,佐藤孝道,小栗隆:オメプラゾールによる女性化乳房が疑われた1例.診断と治療 84 (増刊号):351,1996

• 30) Lindquist M, Edwers IR:Endocrine advers effects of omeprazole. BMJ 305:451-452,1992

• 31) Shiba S, Sugiura K, Ebata A et al:Hyponatremia with consciousness disturbance caused by omeprazole administration. A case report and literature review. Dig Dis Sci 41:1615-1617,1996
  pubmed

• 32) Landell L, Havu N, Anderson A et al:Gastritis development and acid suppression therapy revisited. Results of randomized clinical study with long-term follow-up(abstr).Gastroenterology 112:A28,1998

• 33) Uemura N, Oomoto Y, Mukai T et al:Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients. Aliment Pharmacol Ther 11:793-800,1997
  pubmed

• 34) 上村直実,岡本志朗:Helicobacter pylori陽性症例における PPI投与と炎症の進展.臨牀消化器内科 13:1399-1405,1998

• 35) Modlin IM, Sachs G:2.胃酸分泌の調節,第2章胃酸分泌.胃酸関連疾患の病態と治療,中澤三郎監訳,医学書院,東京,2000,pp62-90

• 36) Navarro JF, Gallego E, Aviles J:Recurrent severe acute hepatitis and omeprazole. Ann lnt Med 127:1135-1136,1997

• 37) Koury SI, Stone CK, LaCharite DD et al:Acute hepatitis induced by omeprazole. Am J Emerg Med 16:550-551,1998

Part7 Compliance プロトンポンプ阻害薬の課題と展望

P.253 掲載の参考文献

• 1) Havu N:Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35 (suppl 1):42-55,1986

• 2) Havu N, Mattsson H, Ekman L et al:Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45:189-195,1990
  pubmed

• 3) Larsson H, Carlsson E, Mattsson H et al:Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Gastroenterology 90:391-399,1986

• 4) Eissele R, Patberg H, Koop H et al:Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria. Gastroenterology 103:1596-1601,1992
  pubmed

• 5) Mattsson H, Havu N, Brautigam J et al:Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like-cell carcinoids in the rat. Gastroenterology 100:311-319,1991
  pubmed

• 6) Ryberg B, Axelson J, Hakanson R et al:Trophic effects of continuous infusion of (Leu 15)-gastrin-17 in the rat. Gastroenterology 98:33-38,1990

• 7) Kuipers EJ, Uyterlinde AM, Pena AS et al:Long-term sequelae of Heltcobacter pylori gastritis. Lancet 345:1525-1528,1995
  pubmed

• 8) Kuipers EJ, Uyterlinde AM, Pena As et al:Increase of Helicobacter pylorti-associated corpus gastritis during acid suppressive therapy:implications for long-term safety. Am J Gastroenterol 90:1401-1406,1995
  pubmed

• 9) Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al:Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 334:1018-1022,1996.
  pubmed

• 10) Sachs G:Gastritis, Helicobacter pylori, and proton pump inhibitors.Gastroenterology 112:1033-1036,1997
  pubmed

• 11) Lundell L, Havu N, Andersson A et al:Gastritis development and acid suppression therapy revisited. Results of a randomised clinical study with long-term follow-up. DDW, Washington,DC,1997

• 12) Lundell L, Miettinen P, Myrvold HE et al:Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 117:319-326,1999

• 13) Assouad M, Vicks SL, Pokroy MV et al:Recarrent acute interstitial nephritis on rechallenge with omeprazole. Lancet 344:549,1994
  pubmed

• 14) Jones B, Hewson E, Price A:Acute interstitial nephritis due to omeprazole. Lancet 344:1017-1018,1994
  pubmed

• 15) Schonhofer PS:Intravenous omeprazole and blindness. Lancet 343:665 1994

• 16) Garcia Rodriguez LA, Mannino S, Wallander MA et al:A cohort study of the ocular safety of anti-ulcer drugs. Br J Clin Phamacol 42:213-216,1996

• 17) 河野通盛,山田稔,奥村剛清ほか:プロトンポンプ阻害剤により視力障害をきたした2症例. 日消誌 97:575-579,2000
  Medical*Online

P.259 掲載の参考文献

• 1) Hatlebakk JG, Berstad A, Carling L et al:Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scandinavian multicentre trial. Scand J Gastroenterol 28:224-228,1993
  pubmed

• 2) Ekstrom P, Carling L, Unge P:Lansoprasole versus omeprazole in active duodenal ulcer. A double-blind, ramdomized, comparative study. Scand J Gastroenterol 30:210-215, 1995

• 3) Hirschowitz BI,Mohnen J, Shaw S:Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 10:507-522,1996
  pubmed

• 4) Verdu EF, Fraser R, Armstrong D et al:Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori positive volunteers. Scand J Gastroenterol 29:1065-1069,1994
  pubmed

• 5) Bruley des Varannes S, Levy P, Lartigue S et al:Comparison of lansoprazole with omeprazole on 24-hour intragastric pH,acid secretion and serum gastrin in healthy volunteers. Aliment Pharmaco Ther 8:309-314,1994.

• 6) McColl KE, Nulimi AM, Dorrian CA et al:Helicobacter pylori and hypergastrinemia during proton pump inhibitor therapy. Scand J Gastroenterol 27:93-98,1992

• 7) Verdu EF, Armstrong D, Fraser R et al:Effect of Helicobater pylori status on intragastric pH during treatment with omeprazole. Gut 36:539-543,1995

• 8) Verdu EF, Armstrong D, Idstrom Jp et al:Effect of curing Helicbbacter pylori infection on intragastric pH during treatment with omeprazole. Gut 37:743-748,1995
  pubmed

• 9) Marshall BJ:Helicobacter pylori. Am J Gastroenterol 89(suppl 8):S116-S128,1994

• 10) Pounder RE, Ng D:The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9 (suppl 2):33-39,1995

• 11) Roosendaal R, Kuipers EL, Bluitenwerf et al:Helicobacter pylori and the birth cohort effect:evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 92:1480-1482,1997

• 12) Geus WP, Mulder PGH, Nicolai JJ et al:Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Parmacol Ther 12:329-335,1998

P.263 掲載の参考文献

• 1) Bell NI, Hunt RH:Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33:118-124,1992

• 2) Leite LP, Johnston BT, Just RJ et al:Persistent acid secretion during omeprazole therapy:a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 91:1527-1531,1996
  pubmed

• 3) Katzka DA, Paoletti V, Leite L et al:Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms:testing while on therapy identifies the need for more aggressive anti-reflux therapy.Am J Gastroenterol 91:2110-2113,1996

• 4) Peghini PL, Katz PO, Bracy NA et al:Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767,1998
  pubmed

• 5) Hatlebakk JG, Katz Po, Kuo B et al:Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 12:1235-1240,1998
  pubmed

• 6) Peghini PL, Katz PO, Castell DO:Ranitidine control nocturnal gastric acid breakthrough on omeprazole:a controlled study in normal subjects. Gastroenterology 115:1335-1339,1998
  pubmed

• 7) Katsube T, Adachi K, Kawamura A et al:Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049-1056,2000
  pubmed

• 8) Katz PO, Anderson C, Khoury R et al:Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 12:1231-1234,1998
  pubmed

• 9) Fouad YM, Katz PO, Castell DO:Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 13:1467-1471,1999
  pubmed

• 10) Adachi K, Katsube T, Kawamura A et al:CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 14:1259-1266,2000
  pubmed

• 11) Holtmann G, Cain C, Malfertheiner P:Gastric Heliobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 117:11-16,1999

• 12) Martinek J, Kuzela L, Spicak J et al:Review article:the clinical influence of Helicobacter pylori in effective acid suppression-implications for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:979-990,2000
  pubmed

• 13) Bercik P, Verdu EF, Armstrong D:The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 95:947-955,2000
  pubmed

• 14) van Herwaarden MA, Samsom M, Smout AJ:Helicobater pylori eradication increases nocturnal acid breakthrough [letter]. Aliment Pharmacol Ther 14:961-962,2000

• 15) Adachi K, Fujishiro H, Katsube T et al:Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191-1196,2001

• 16) Nwokolo CU, Smith JT, Gavey C et al:Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 4:29-45,2000

• 17) Frakler WK, Ours TM, Varezi MF et al:H2RAs do not provide sustained suppression of nocturnal acid breakthrough. Gastroenterology 120 (suppl 1):A33-A34,2001

• 18) Kinoshita Y, Kawanami C, Kishi K et al:Helicobacter. pylori independent chronological change in gastric acid secretion in the Japanese. Gut 41:452-458,1997
  pubmed

P.268 掲載の参考文献

• 1) 岡野憲義:胃潰瘍赤色癩痕期 (S1期) から白色癩痕期 (S2期) への移行に関する臨床的研究. 日大医誌 51:492-498,1992

• 2) 横山靖,西元寺克禮,大井田正人:胃・十二指腸潰瘍維持療法下の再発に関する臨床的および内視鏡的研究.Gastroenterol Endosc 29:40-53,1987

• 3) 斉藤秀樹,小松博,新沢陽英ほか:胃・十二指腸潰瘍に対するプロトンポンプ阻害剤ランソプラゾールのS2移行率の検討. Ther Res 16:2741-2750,1995

• 4) 倉井亮,清水哲,斉藤有一ほか:胃潰瘍に対する lansoprazoleの治療効果の検討-ヒスタミンH2受容体拮抗剤との比較-. 医学と薬学 36:1007-1013,1996

• 5) 馬場忠雄,細田四郎,古川裕夫ほか:胃潰瘍におけるOmeprazole (Omepral) とH2受容体拮抗薬の廠痕治癒の形態比較. 新薬と臨牀 46:46-60,1997

• 6) 三浦総一郎,土屋雅春, 石井裕正:Lansoprazole による消化性潰瘍初期治療後の再発率の検討- Famotidineとの比較検討-. 薬理と治療 24:1083-1096,1996
  Medical*Online

• 7) 岡井高,坂井潤太,大坪公士朗ほか:超音波内視鏡から見たランソプラゾールによる胃潰瘍の治癒効果について; ファモチジンとの比較. 新薬と臨牀 43:2631-2638,1994

• 8) 岡田光男,八尾恒良,吉永一彦ほか:難治性潰瘍-X線所見を中心に.胃と腸 27:1365-1383,1992

• 9) 木村明,瀬尾充,桜井俊弘ほか:胃潰瘍の治癒予測因子に関する研究-多重ロジスティックモデルを用いた検討-.日本消化器病学会雑誌 92:769-799,1995

• 10) 盧田潔,坂口正博,大坂直文ほか:病態生理からみた難治性胃潰瘍.胃と腸 27:1357-1364,1992

• 11) 竹山泰守,松井敏幸,八尾恒良ほか:胃体部潰瘍に対するH2受容体拮抗剤とプロトンポンプインヒビターの効果比較-prospective controlled study-.日本消化器病学会雑誌 96:502-510,1999

• 12) chiba N, De Gara CJ, Wilkinson JM et al:Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease:A meta-analysis. Gastroenterology 112:1798-1810,1997
  pubmed

• 13) 羽生泰樹,清田啓介,浅田全範ほか:軽症逆流性食道炎治療におけるオメプラゾールとファモチジンの無作為比較対照試験.新薬と臨牀 49:1072-1078,2000
  Medical*Online

• 14) 原澤茂,三輪剛,西元寺克禮ほか:逆流性食道炎に対する Lansoprazole の有用性の検討-H2-Ra とのクロスオーバー比較試験-. Progress in Medicine 19:931-939,1999
  Medical*Online

• 15) Yeomans ND, Tulassay Z, Juhaszl. et al:A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial:Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT).N Engl J Med 338:719-726,1998

• 16) Green Fw Jr., Kaplan MM, Curtis LE et al:Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 74:38-43,1978
  pubmed

• 17) 三好秋馬,豊田隆謙,松尾裕ほか:Omeprazole 注射剤の24時間胃内pHに関する研究; 単回投与試験. 薬理と治療 23 (suppl 8):S2107,1995

• 18) 森治樹,高橋春樹,岡野晃ほか:Omeprazole注射剤の臨床薬理試験:胃液分泌抑制効果.薬理と治療 23 (suppl 8):S2097-S2105,1995

• 19) 三好秋馬,谷内昭,崎田隆夫ほか:H2受容体拮抗剤Famotidine注の胃液分泌抑制作用:テトラガストリン, ペタゾール刺激分泌抑制効果.基礎と臨床 17:2917-2927,1983

• 20) 三好秋馬,青木照明,中島光好ほか:上部消化管出血に対するOmeprazole注射剤の臨床的研究Famotidine注射剤を対照薬とした二重盲検比較試験-.新薬と治療 23 (suppl 8):S1593-S1608,1995

• 21) Yoshida N, Granger DN, Evans DJ Jr et al:Mechanisms involved in Helicobacter pylori induced inflammation. Gastroenterology 105:1431-1440,1993
  pubmed

• 22) Yoshida N, Kassai K, Tanaka Y et al:Helicobacter pylori water extract induces upregulation of adhesion molecule on endothelial cells. Dig Dis Sci(in press)

• 23) Yoshida N, Yoshikawa T, Tanaka Y et al:A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14 (suppl 1):74-81,2000

• 24) wandall JH:Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 33:617-621,1992
  pubmed

• 25) Suzuki M, Mori M, Miura S et al:Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 21:727-731,1996
  pubmed

• 26) Handa O, Yoshida N, Ishikawa T et al:inhibitory effects of proton pump inhibitors on IL-8 production and neutrophil migration. Gastroenterology 120:A147,2001

P.273 掲載の参考文献

• 1) 浅香正博,武田宏司,加藤元嗣:消化性潰瘍の治療.日本医事新報 3578:10-15,1996

• 2) Lind T, Cederbreg C, Ekenved G et al:Effect of omeprazole-a gastri proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 24:270-276,1983

• 3) 河合隆,池田肇,斉藤利彦ほか:プロトンポンプインヒビター (AG-1749 ならびに E-3810) の長期投与後の変化について.日本臨床 50:188-193,1992
  Medical*Online

• 4) Helander HF, Mattsson H, Ottosson S:Structure and function of rat parietal cells during treatment with omeplazole, SCH28080, SCH32651,or ranitidine. Scand J Gastroenterol 25:799-809,1990
  pubmed

• 5) Li H, Helander HF:Parietal cell kinetics after administration of omeplazole and ranitidine in the rat. Scand J Gastroenterol 30:205-209,1995

• 6) 河合隆:プロトンポンプ阻害剤投与による壁細胞の空胞化変性ならびに長期投与後の胃酸分泌について.消化性潰瘍の薬物療法のあり方をめぐって,並木正義編,医学図書出版,東京,1992,pp228-234

• 7) Furuhashi M, Nakahara A, Fukutomi H et al:Changes in subcellular structures of parietal cells in the rat gastric gland after omeprazole. Arch Histrol Cytol 55:191-201,1992
  pubmed

• 8) Ekman L, Hansson E, Have N et al:Toxicological studies on omeprazole. Scand J Gastroenterol Suppl 108:53-69,1985

• 9) 河合隆,三輪一彦,斉藤利彦ほか:各種 PPI の酸分泌抑制の特徴.GIResearch 1:274-280,1993

• 10) Eissele R, Patberg H, Koop H et al:Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria. Gastroenology 103:1596-1601,1992

• 11) stachura J, Tarnawski A, Gergely H et al:Age associated hyperplasia of Enterochromaffin-like cells in the gastric exyntic mucosa of rats. Gastroenterlogy 92:1651,1987

• 12) 小越和栄,加藤俊幸:プロトンポンプ阻害薬の長期投与とその安全性.治療学 28:421-424,1994
  Medical*Online

• 13) Joelson s, Joelson IB, Lundborg P et al:Digestion 51 (suppl):93-101,1992

• 14) 中村正彦,秋葉保忠,石井裕正ほか:PPI長期投与時のECL細胞,壁細胞の変化-胃粘膜内Lansoprazole結合部位のRadioautography法による検討.Ther Res 19 (suppl 1)131-135,1998

• 15) Iwai T, Satoh H, Nakao M et al:Lansoprazole,a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents chemother 35:490-496,1991

• 16) Figura N, Crabtree JE, Dattilo M:In vitro activity of lansoprazole against Helicobater pylori.J Antimicrob Chemother 39:585-590,1997

• 17) Scaringi L, Cornacchione P, Fettucciari K et al:Activity inhibition of cytolytic-lymphocites by omeprazole. Scand J lmmunol 44:204-214,1996

• 18) Suzuki M, Nakamura M, Mori M et al:Lansoprazole inhibits oxygen-derived free radica production from neutrophils activated by Helocobacter pulori.J Clin Gastroenterol 20 (suppl 2):S93-S96,1995

• 19) 国崎主税,杉山貢,土屋周二:酸分泌抑制剤の長期投与に伴う防御因子の変化.Ther Res 11 (suppl 1):47-55,1990

• 20) Kakei N, Ichinose M, Tsukada S et al:Omeplazol, a proton pump inhibitor, reduces the secretion, synthesis and gene expression of pepsinogen in the rat stomach. Biochem Biophys Res Commun 195:997-1004,1993
  pubmed

• 21) Solvell L:The clinical safety of omeprazole. Scand J Gastroenterol Suppl 166:106-110,1989
  pubmed